EP3486246A1 - Thieno[2,3-c]pyrans as cftr modulators - Google Patents

Thieno[2,3-c]pyrans as cftr modulators Download PDF

Info

Publication number
EP3486246A1
EP3486246A1 EP18181140.7A EP18181140A EP3486246A1 EP 3486246 A1 EP3486246 A1 EP 3486246A1 EP 18181140 A EP18181140 A EP 18181140A EP 3486246 A1 EP3486246 A1 EP 3486246A1
Authority
EP
European Patent Office
Prior art keywords
pyran
thieno
tetramethyl
carboxamide
carbamoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18181140.7A
Other languages
German (de)
English (en)
French (fr)
Inventor
Steven Emiel VAN DER PLAS
Sébastien Laurent Xavier MARTINA
Sébastien Jean-Jacques Cédric DROPSIT-MONTOVERT
Martin James Inglis Andrews
Hans KELGTERMANS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51300734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3486246(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201317935A external-priority patent/GB201317935D0/en
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of EP3486246A1 publication Critical patent/EP3486246A1/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Definitions

  • the present invention relates to compounds that are modulators of cystic fibrosis Transmembrane Conductance regulator (CFTR), and their use in the treatment of cystic fibrosis.
  • the present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, and methods for the treatment of cystic fibrosis by administering a compound of the invention.
  • CFTR cystic fibrosis Transmembrane Conductance regulator
  • ABC transporters are a family of homologous membrane transporter proteins regulating the transport of a wide variety of pharmacological agents (for example drugs, xenobiotics, anions, etc%) that bind and use cellular adenosine triphosphate (ATP) for their specific activities. Some of these transporters were found to defend malignant cancer cells against chemotherapeutic agents, acting as multidrug resistance proteins (like the MDR1-P glycoprotein, or the multidrug resistance protein, MRP 1). So far, 48 ABC transporters, grouped into 7 families based on their sequence identity and function, have been identified.
  • pharmacological agents for example drugs, xenobiotics, anions, etc.
  • ATP cellular adenosine triphosphate
  • ABC transporters provide protection against harmful environmental compounds by regulating a variety of important physiological roles within the body, and therefore represent important potential drug targets for the treatment of diseases associated with transporter defects, outwards cell drug transport, and other diseases in which modulation of ABC transporter activity may be beneficial.
  • CFTR The cAMP/ATP-mediated anion channel, CFTR, is one member of the ABC transporter family commonly associated with diseases, which is expressed in a variety of cells types, including absorptive and secretory epithelia cells, where it regulates anion flux across the membrane, as well as the activity of other ion channels and proteins.
  • the activity of CFTR in epithelial cells is essential for the maintenance of electrolyte transport throughout the body, including respiratory and digestive tissue. (Quinton, 1990)
  • CFTR The gene encoding CFTR has been identified and sequenced (Kerem et al., 1989).
  • CFTR comprises about 1480 amino acids that encode a protein made up of a tandem repeat of transmembrane domains, each containing six transmembrane helices and a nucleotide binding domain.
  • the pair of transmembrane domains is linked by a large, polar, regulatory (R)-domain with multiple phosphorylation sites that regulate channel activity and cellular trafficking.
  • Cystic fibrosis is caused by a defect in this gene which induces mutations in CFTR. Cystic fibrosis is the most common fatal genetic disease in humans, and affects ⁇ 0.04% of white individuals(Bobadilla et al., 2002), for example, in the United States, about one in every 2,500 infants is affected, and up to 10 million people carry a single copy of the defective gene without apparent ill effects; moreover subjects bearing a single copy of the gene exhibit increased resistance to cholera and to dehydration resulting from diarrhea. This effect might explain the relatively high frequency of the CF gene within the population.
  • CF patients Beyond respiratory disease, CF patients also suffer from gastrointestinal problems and pancreatic insufficiency that result in death if left untreated. Furthermore, female subjects with cystic fibrosis suffer from decreased fertility, whilst males with are infertile.
  • the mutation results in defective channel gating. Indeed, even if ⁇ F508-CFTR is allowed to reach the cell plasma membrane by low-temperature (27°C) rescue where it can function as a cAMP-activated chloride channel, its activity is decreased significantly compared with WT-CFTR (Pasyk and Foskett, 1995).
  • mutations with lower incidence have also been identified that alter the channel regulation or the channel conductance.
  • the mutated protein is properly trafficked and localized to the plasma membrane but either cannot be activated or cannot function as a chloride channel (e.g. missense mutations located within the nucleotide binding domains), examples of these mutations are G551D, G178R, G1349D.
  • Mutations affecting chloride conductance have a CFTR protein that is correctly trafficked to the cell membrane but that generates reduced chloride-flow (e.g. missense mutations located within the membrane-spanning domain), examples of these mutations are R117H, R334W.
  • CFTR activity modulation may be beneficial for other diseases not directly caused by mutations in CFTR, such as, for example, chronic obstructive pulmonary disease (COPD), dry eye disease, and Sjogren's Syndrome.
  • COPD chronic obstructive pulmonary disease
  • COPD dry eye disease
  • Sjogren's Syndrome a chronic obstructive pulmonary disease
  • COPD is characterized by a progressive and non-reversible airflow limitation, which is due to mucus hypersecretion, bronchiolitis, and emphysema.
  • a potential treatment of mucus hypersecretion and impaired mucociliary clearance that is common in COPD could consist in using activators of mutant or wild-type CFTR.
  • the anion secretion increase across CFTR may facilitate fluid transport into the airway surface liquid to hydrate the mucus and optimize periciliary fluid viscosity.
  • the resulting enhanced mucociliary clearance would help in reducing the symptoms associated with COPD.
  • Dry eye disease is characterized by a decrease in tear production and abnormal tear film lipid, protein and mucin profiles. Many factors may cause dry eye disease, some of which include age, arthritis, Lasik eye surgery, chemical/thermal burns, medications, allergies, and diseases, such as cystic fibrosis and Sjogrens's syndrome. Increasing anion secretion via CFTR could enhance fluid transport from the corneal endothelial cells and secretory glands surrounding the eye, and eventually improve corneal hydration, thus helping to alleviate dry eye disease associated symptoms.
  • Sjogrens's syndrome is an autoimmune disease where the immune system harms moisture-producing glands throughout the body, including the eye, mouth, skin, respiratory tissue, liver, vagina, and gut.
  • the ensuing symptoms include, dry eye, mouth, and vagina, as well as lung disease.
  • Sjogrens's syndrome is also associated with rheumatoid arthritis, systemic lupus, systemic sclerosis, and polymypositis/dermatomyositis.
  • the cause of the disease is believed to lie in defective protein trafficking, for which treatment options are limited.
  • modulation of CFTR activity may help hydrating the various organs and help to elevate the associated symptoms.
  • the defective protein trafficking induced by the ⁇ F508-CFTR has been shown to be the underlying basis for a wide range of other diseases, in particular diseases where the defective functioning of the endoplasmic reticulum (ER) may either prevent the CFTR protein to exit the cell, and/or the misfolded protein is degraded (Morello et al., 2000; Shastry, 2003; Zhang et al., 2012).
  • a number of genetic diseases are associated with a defective ER processing equivalent to the defect observed with CFTR in CF such as glycanosis CDG type 1, hereditary emphysema ( ⁇ -1-antitrypsin (PiZ variant)), congenital hyperthyroidism, osteogenesis imperfecta (Type I, II, or IV procollagen), hereditary hypofibrinogenemia (fibrinogen), ACT deficiency ( ⁇ -1-antichymotrypsin), diabetes insipidus (DI), neurophyseal DI (vasopvessin hormoneN2-receptor), neprogenic DI (aquaporin II), Charcot-Marie Tooth syndrome (peripheral myelin protein 22), Perlizaeus-Merzbacher disease, neurodegenerative diseases such as Alzheimer's disease (APP and presenilins), Parkinson's disease, amyotrophic lateral sclerosis, progressive supranuclear plasy, Pick's disease, several
  • anion secretion reduction by CFTR modulators may be beneficial for the treatment of secretory diarrheas, in which epithelial water transport is dramatically increased as a result of secretagogue activated chloride transport.
  • the mechanism involves elevation of cAMP and stimulation of CFTR.
  • the present invention discloses compounds that may act as CFTR modulators for the treatment of cystic fibrosis.
  • the present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds and methods for the treatment of cystic fibrosis by administering the compounds of the invention.
  • Figure 1 shows the current increase measured in the TECC assay for comparative compound and a compound of the invention at various concentration of test compound (50, 100, and 200 nM)
  • the present invention is based on the identification of novel compounds, and their ability to act as CFTR modulators and that they may be useful for the treatment of cystic fibrosis.
  • the present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds and methods for the treatment of cystic fibrosis by administering compounds of the invention.
  • the compounds of the invention are provided for use in the treatment of cystic fibrosis.
  • the compounds of the invention are provided for use in the treatment of cystic fibrosis caused by class I, II, III, IV, and/or VI mutations.
  • the compounds of the invention have a potentiator activity.
  • the compounds of the invention exhibit low activity on CYP enzymes, which may result in low drug-drug interaction potential, and accordingly may be advantageous for patients under multiple therapies.
  • the present invention provides pharmaceutical compositions comprising a compound of the invention, and a pharmaceutical carrier, excipient or diluent.
  • the pharmaceutical composition may additionally comprise further therapeutically active ingredients suitable for use in combination with the compounds of the invention.
  • the further therapeutically active ingredient is an agent for the treatment of cystic fibrosis.
  • the compounds of the invention useful in the pharmaceutical compositions and treatment methods disclosed herein, are pharmaceutically acceptable as prepared and used.
  • this invention provides a method of treating a mammal, in particular humans, with a condition selected from among those listed herein, and particularly cystic fibrosis, which method comprises administering an effective amount of the pharmaceutical composition or compounds of the invention as described herein.
  • the present invention also provides pharmaceutical compositions comprising a compound of the invention, and a suitable pharmaceutical carrier, excipient or diluent for use in medicine.
  • the pharmaceutical composition is for use in the treatment of cystic fibrosis.
  • this invention provides methods for synthesizing the compounds of the invention, with representative synthetic protocols and pathways disclosed later on herein.
  • analogue means one analogue or more than one analogue.
  • 'Alkyl' means straight or branched aliphatic hydrocarbon with the number of carbon atoms specified. Particular alkyl groups have 1 to 8 carbon atoms. More particular is lower alkyl which has 1 to 6 carbon atoms. A further particular group has 1 to 4 carbon atoms. Exemplary straight chained groups include methyl, ethyl n-propyl, and n-butyl. Branched means that one or more lower alkyl groups such as methyl, ethyl, propyl or butyl is attached to a linear alkyl chain, exemplary branched chain groups include isopropyl, iso-butyl, t-butyl and isoamyl.
  • alkoxy' refers to the group -OR 26 where R 26 is alkyl with the number of carbon atoms specified.
  • Particular alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.
  • Particular alkoxy groups are lower alkoxy, i.e. with between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 and 4 carbon atoms.
  • 'Alkylene' refers to divalent alkene radical groups having the number of carbon atoms specified, in particular having 1 to 6 carbon atoms and more particularly 1 to 4 carbon atoms which can be straight-chained or branched. This term is exemplified by groups such as methylene (-CH 2 -), ethylene (-CH 2 -CH 2 -), or -CH(CH 3 )- and the like.
  • alkenyl' refers to monovalent olefinically (unsaturated) hydrocarbon groups with the number of carbon atoms specified.
  • Particular alkenyl has 2 to 8 carbon atoms, and more particularly, from 2 to 6 carbon atoms, which can be straight-chained or branched and having at least 1 and particularly from 1 to 2 sites of olefinic unsaturation.
  • 'Amino' refers to the radical -NH 2 .
  • 'Aryl' refers to a monovalent aromatic hydrocarbon group derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
  • aryl refers to an aromatic ring structure, monocyclic or polyyclic, with the number of ring atoms specified.
  • the term includes groups that include from 6 to 10 ring members. Where the aryl group is a monocyclic ring system it preferentially contains 6 carbon atoms.
  • Particularly aryl groups include phenyl, naphthyl, indenyl, and tetrahydronaphthyl.
  • 'Cycloalkyl refers to a non-aromatic hydrocarbyl ring structure, monocyclic or polycyclic, with the number of ring atoms specified.
  • a cycloalkyl may have from 3 to 10 carbon atoms, and in particular from 3 to 7 carbon atoms.
  • Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
  • 'Cyano' refers to the radical -CN.
  • 'Halo' or 'halogen' refers to fluoro (F), chloro (CI), bromo (Br) and iodo (I). Particular halo groups are either fluoro or chloro.
  • Hetero when used to describe a compound or a group present on a compound means that one or more carbon atoms in the compound or group have been replaced by a nitrogen, oxygen, or sulfur heteroatom. Hetero may be applied to any of the hydrocarbyl groups described above such as alkyl, e.g. heteroalkyl, cycloalkyl, e.g. heterocycloalkyl, aryl, e.g. heteroaryl, and the like having from 1 to 4, and particularly from 1 to 3 heteroatoms, more typically 1 or 2 heteroatoms, for example a single heteroatom.
  • Heteroaryl' means an aromatic ring structure, monocyclic or polycyclic, that includes one or more heteroatoms independently selected from O, N and S and the number of ring atoms specified.
  • the aromatic ring structure may have from 5 to 10 ring members.
  • the heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a bicyclic structure formed from fused five and six membered rings or two fused six membered rings or, by way of a further example, two fused five membered rings.
  • Each ring may contain up to four heteroatoms typically selected from nitrogen, sulphur and oxygen.
  • the heteroaryl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom.
  • the heteroaryl ring contains at least one ring nitrogen atom.
  • the nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.
  • Examples of five membered monocyclic heteroaryl groups include but are not limited to pyrrole, furan, thiophene, imidazole, furazan, oxazole, oxadiazole, oxatriazole, isoxazole, thiazole, isothiazole, pyrazole, triazole and tetrazole groups.
  • Examples of six membered monocyclic heteroaryl groups include but are not limited to pyridine, pyrazine, pyridazine, pyrimidine and triazine.
  • bicyclic heteroaryl groups containing a five membered ring fused to another five membered ring include but are not limited to imidazothiazole and imidazoimidazole.
  • bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzfuran, benzthiophene, benzimidazole, benzoxazole, isobenzoxazole, benzisoxazole, benzthiazole, benzisothiazole, isobenzofuran, indole, isoindole, isoindolone, indolizine, indoline, isoindoline, purine (e.g.
  • bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinoline, isoquinoline, chroman, thiochroman, chromene, isochromene, chroman, isochroman, benzodioxan, quinolizine, benzoxazine, benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and pteridine groups.
  • Particular heteroaryl groups are those derived from thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole and pyrazine.
  • heterocycloalkyl means a stable non-aromatic ring structure, monocyclic or polycyclic, that includes one or more heteroatoms independently selected from O, N and S and the number of ring atoms specified.
  • the non-aromatic ring structure may have from 4 to 10 ring members, and in particular from 4 to 7 ring members.
  • a fused heterocyclic ring system may include carbocyclic rings and need only to include one heterocyclic ring. Examples of heterocyclic rings include, but are not limited to, morpholine, piperidine ( e.g. 1-piperidinyl, 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), pyrrolidine (e.g.
  • Still further examples include azetidine, piperidone, piperazone, and N-alkyl piperidines such as N-methyl piperidine.
  • heterocycloalkenyl means a 'heterocycloalkyl, wherein one bond of the ring is reduced, thus the ring comprises a double bond.
  • 'Hydroxyl' refers to the radical -OH.
  • 'Substituted' refers to a group in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s).
  • 'Sulfo' or 'sulfonic acid' refers to a radical such as -SO 3 H.
  • 'Thiol' refers to the group -SH.
  • term 'substituted with one or more' refers to one to four substituents. In one embodiment it refers to one to three substituents. In further embodiments it refers to one or two substituents. In a yet further embodiment it refers to one substituent.
  • 'Thioalkoxy' refers to the group -SR 26 where R 26 has the number of carbon atoms specified and particularlyC 1 -C 8 alkyl.
  • Particular thioalkoxy groups are thiomethoxy, thioethoxy, n-thiopropoxy, isothiopropoxy, n-thiobutoxy, tert-thiobutoxy, sec-thiobutoxy, n-thiopentoxy, n-thiohexoxy, and 1,2-dimethylthiobutoxy.
  • Particular thioalkoxy groups are lower thioalkoxy, i.e. with between 1 and 6 carbon atoms. Further particular alkoxy groups have between 1 and 4 carbon atoms.
  • heterocyclic ring may have one to four heteroatoms so long as the heteroaromatic ring is chemically feasible and stable.
  • 'Pharmaceutically acceptable means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly, in humans.
  • 'Pharmaceutically acceptable salt' refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound.
  • such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts.
  • such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid
  • Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.
  • the term 'pharmaceutically acceptable cation' refers to an acceptable cationic counter-ion of an acidic functional group. Such cations are exemplified by sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium cations, and the like.
  • 'Pharmaceutically acceptable vehicle' refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered.
  • Prodrugs' refers to compounds, including derivatives of the compounds of the invention,which have cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo.
  • Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.
  • 'Solvate' refers to forms of the compound that are associated with a solvent, usually by a solvolysis reaction. This physical association includes hydrogen bonding.
  • Conventional solvents include water, ethanol, acetic acid and the like.
  • the compounds of the invention may be prepared e.g. in crystalline form and may be solvated or hydrated.
  • Suitable solvates include pharmaceutically acceptable solvates, such as hydrates, and further include both stoichiometric solvates and non-stoichiometric solvates. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid.
  • 'Solvate' encompasses both solution-phase and isolable solvates.
  • Representative solvates include hydrates, ethanolates and methanolates.
  • 'Subject' includes humans.
  • the terms 'human', 'patient' and 'subject' are used interchangeably herein.
  • 'Effective amount means the amount of a compound of the invention that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease.
  • the "effective amount” can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated.
  • 'Treating' or 'treatment' of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e. arresting the disease or reducing the manifestation, extent or severity of at least one of the clinical symptoms thereof).
  • 'treating' or 'treatment' refers to ameliorating at least one physical parameter, which may not be discernible by the subject.
  • 'treating' or 'treatment' refers to modulating the disease or disorder, either physically, ( e.g. stabilization of a discernible symptom), physiologically, ( e.g. stabilization of a physical parameter), or both.
  • "treating" or "treatment” relates to slowing the progression of the disease.
  • Class I mutation(s) refers to mutations which interfere with protein synthesis. They result in the introduction of a premature signal of termination of translation (stop codon) in the mRNA. The truncated CFTR proteins are unstable and rapidly degraded, so, the net effect is that there is no protein at the apical membrane.
  • Class I mutation(s) refers to p.Gly542X (G542X), W1282X, c.489+1G>T (621+1G>T), or c.579+1G>T (711+1G>T) mutation. More particularly, Class I mutation(s) refers to G542X; or W1282X mutations.
  • Class II mutation(s) refers to mutations which affect protein maturation. These lead to the production of a CFTR protein that cannot be correctly folded and/or trafficked to its site of function on the apical membrane.
  • Class II mutation(s) refers to p.Phe508del (F508del), p.Ile507del, or p.Asn1303Lys (N1303K) mutations. More particularly, Class II mutation(s) refers to F508del or N1303K mutations.
  • Class III mutation(s) refers to mutations which alter the regulation of the CFTR channel.
  • the mutated CFTR protein is properly trafficked and localized to the plasma membrane but cannot be activated, or it cannot function as a chloride channel.
  • Class III mutation(s) refers to p.Gly551Asp (G551D), G551S, R553G; G1349D; S1251N, G178R, S549N mutations. More particularly, Class III mutation(s) refers to G551D, R553G, G1349D, S1251N, G178R, or S549N mutations.
  • Class IV mutation(s) refers to mutations which affect chloride conductance.
  • the CFTR protein is correctly trafficked to the cell membrane but generates reduced Cl- flow or a "gating defect" (most are missense mutations located within the membrane-spanning domain).
  • Class IV mutation(s) refers to p.Arg117His (R117H), R347P, or p.Arg334Trp (R334W) mutations.
  • Class V mutation(s) refers to mutations which reduce the level of normally functioning CFTR at the apical membrane or result in a "conductance defect" (for example partially aberrant splicing mutations or inefficient trafficking missense mutations).
  • Class V mutation(s) refers to c.1210-12T[5] (5T allele), c.3140-26A>G (3272-26A>G), c.3850-2477C>T (3849+10kbC>T) mutations.
  • Class VI mutation(s) refers to mutations which decrease the stability of the CFTR which is present or which affect the regulation of other channels, resulting in inherent instability of the CFTR protein. In effect, although functional, the CFTR protein is unstable at the cell surface and it is rapidly removed and degraded by cell machinery.
  • Class VI mutation(s) refers to Rescued F508del, 120del23, N287Y, 4326dellTC, or 4279insA mutations. More particularly, Class VI mutation(s) refers to Rescued F508del mutations.
  • Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are particularly useful prodrugs.
  • double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
  • Particular such prodrugs are the C 1 - 8 alkyl, C 2 - 8 alkenyl, C 6-10 optionally substituted aryl, and (C 6 - 10 aryl)-(C 1-4 alkyl) esters of the compounds of the invention.
  • the term 'isotopic variant' refers to a compound that contains unnatural proportions of isotopes at one or more of the atoms that constitute such compound.
  • an 'isotopic variant' of a compound can contain one or more non-radioactive isotopes, such as for example, deuterium ( 2 H or D), carbon-13 ( 13 C), nitrogen-15 ( 15 N), or the like.
  • non-radioactive isotopes such as for example, deuterium ( 2 H or D), carbon-13 ( 13 C), nitrogen-15 ( 15 N), or the like.
  • the following atoms, where present may vary, so that for example, any hydrogen may be 2 H/D, any carbon may be 13 C, or any nitrogen may be 15 N, and that the presence and placement of such atoms may be determined within the skill of the art.
  • the invention may include the preparation of isotopic variants with radioisotopes, in the instance for example, where the resulting compounds may be used for drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • compounds may be prepared that are substituted with positron emitting isotopes, such as 11 C, 18 F, 15 O and 13 N, and would be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.
  • PET Positron Emission Topography
  • Stereoisomers that are not mirror images of one another are termed 'diastereomers' and those that are non-superimposable mirror images of each other are termed 'enantiomers'.
  • a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible.
  • An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory ( i.e. as (+) or (-)-isomers respectively).
  • a chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a 'racemic mixture'.
  • tautomeric forms of the compounds provided herein are intended to be encompassed within the scope of the invention.
  • 'Tautomers' refer to compounds that are interchangeable forms of a particular compound structure, and that vary in the displacement of hydrogen atoms and electrons. Thus, two structures may be in equilibrium through the movement of ⁇ electrons and an atom (usually H).
  • enols and ketones are tautomers because they are rapidly interconverted by treatment with either acid or base.
  • Another example of tautomerism is the aci- and nitro- forms of phenylnitromethane that are likewise formed by treatment with acid or base. Still another example of tautomerism is illustrated below:
  • Tautomeric forms may be relevant to the attainment of the optimal chemical reactivity and biological activity of a compound of interest.
  • the compounds of the invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)- stereoisomers or as mixtures thereof.
  • the present invention is based on the identification of novel compounds, that may be useful for the treatment of cystic fibrosis.
  • the present invention also provides methods for the production of these compounds, pharmaceutical compositions comprising these compounds and methods for the treatment of cystic fibrosis by administering the compounds of the invention.
  • a compound of the invention is according to Formula I, wherein R 1 is C 3-7 mono or spirocyclic cycloalkyl.
  • R 1 is spiro[3.3]heptane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R 1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • a compound of the invention is according to Formula I, wherein R 1 is C 3-7 cycloalkyl.
  • R 1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • a compound of the invention is according to Formula I, wherein R 1 is C 3-7 mono or spirocyclic cycloalkyl substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is spiro[3.3]heptane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 1 is C 3-7 mono or spirocyclic cycloalkyl substituted with one or two independently selected R 2 groups.
  • R 1 is spiro[3.3]heptane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is substituted with one or two independently selected R 2 groups.
  • R 1 is C 3-7 mono or spirocyclic cycloalkyl substituted with one R 2 group.
  • R 1 is spiro[3.3]heptane, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is substituted with one R 2 group.
  • a compound of the invention is according to Formula I, wherein R 1 is C 3-7 cycloalkyl substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 1 is C 3-7 cycloalkyl substituted with one or two independently selected R 2 groups.
  • R 1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is substituted with one or two independently selected R 2 groups.
  • R 1 is C 3-7 cycloalkyl substituted with one R 2 group.
  • R 1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is substituted with one R 2 group.
  • a compound of the invention is according to Formula I, wherein R 1 is C 3-7 cycloalkyl substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 2 is selected from halo, CN, oxo, and OH.
  • R 2 is selected from F, Cl, CN, oxo, and OH.
  • a compound of the invention is according to Formula I, wherein R 1 is C 3-7 cycloalkyl substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 2 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5a , wherein R 5a is as defined above.
  • R 2 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , or - C(CH 3 ) 3 .
  • R 2 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5a .
  • R 2 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, -CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, -CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 -OH, -C(OH)(CH 3 ) 2 , -CF 3 , -CH 2 -CHF 2 , -CH 2 CH 2 OCH 3 , or -CH 2 CH 2 N(CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is C 3-7 cycloalkyl substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 2 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5a , wherein R 5a is as defined above.
  • R 2 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 .
  • R 2 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5a .
  • R 2 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, -CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, -CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -OCH 3 , -OCH 2 -CH 3 , O-CF 3 , -OCH 2 -CHF 2 , -OCH 2 CH 2 OCH 3 , or -OCH 2 CH 2 N(CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is 4-7 membered mono or spirocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is oxa-spiro[3.3]heptane, aza-spiro[3.3]heptane, oxa-6-aza-spiro[3.3]heptane, diaza-spiro[3.3]heptane, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 1 is 4-7 membered mono or spirocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one or two independently selected R 2 groups.
  • R 1 is oxa-spiro[3.3]heptane, aza-spiro[3.3]heptane, oxa-6-aza-spiro[3.3]heptane, diaza-spiro[3.3]heptane, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one or two independently selected R 2 groups.
  • R 1 is 4-7 membered mono or spirocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one R 2 group.
  • R 1 is oxa-spiro[3.3]heptane, aza-spiro[3.3]heptane, oxa-6-aza-spiro[3.3]heptane, diaza-spiro[3.3]heptane, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one R 2 group.
  • a compound of the invention is according to Formula I, wherein R 1 is 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 1 is 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one or two independently selected R 2 groups.
  • R 1 is pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one or two independently selected R 2 groups.
  • R 1 is 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one R 2 group.
  • R 1 is pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one R 2 group.
  • a compound of the invention is according to Formula I, wherein R 1 is 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 2 is selected from halo, CN, oxo, and OH.
  • R 2 is selected from F, Cl, CN, oxo, and OH.
  • a compound of the invention is according to Formula I, wherein R 1 is 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one or more independently selected R 2 groups.
  • a compound of the invention is according to Formula I, wherein R 1 is 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 2 is -CH 3 , -CH 2 CH 3 , CH(CH 3 ) 2 , or -C(CH 3 ) 3 .
  • R 2 is -CH 3 , -CH 2 CH 3 , CH(CH 3 ) 2 , or -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5a .
  • R 2 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , or ,- C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 -OH, -C(OH)(CH 3 ) 2 , -CF 3 , -CH 2 -CHF 2 , -CH 2 CH 2 OCH 3 , or -CH 2 CH 2 N(CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from O, N, and S, substituted with one or more independently selected R 2 groups, and R 2 is as described above.
  • R 1 is pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl, each of which is substituted with one or more independently selected R 2 groups.
  • R 2 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5a , wherein R 5a is as defined above.
  • R 2 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5a .
  • R 2 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 mono or bicyclic aryl. In a particular embodiment, R 1 is phenyl.
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 mono or bicyclic aryl optionally substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl is substituted with one or more independently selected R 3 groups.
  • R 1 is C 6-10 mono or bicyclic aryl, substituted with one or two independently selected R 3 groups.
  • R 1 is phenyl substituted with one or two independently selected R 3 groups.
  • R 1 is C 6-10 mono or bicyclic aryl, substituted with one R 3 group.
  • R 1 is phenyl substituted with one R 3 group.
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 mono or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is selected from halo, CN, and OH.
  • R 3 is selected from F, Cl, CN, and OH.
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 monocyclic or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b .
  • R 3 is -CH 3 , -CH 2 CH 3 , CH(CH 3 ) 2 , -C(CH 3 ) 3 .
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 mono or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b .
  • R 3 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 3 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 3 is -CH 3 , -CH 2 CH 3 , CH(CH 3 ) 2 , -C(CH 3 ) 3 .
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 monocyclic or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b .
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 mono or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b .
  • R 3 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 3 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 monocyclic or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is C 2-4 alkenyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is C 2-4 alkenyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 mono or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is C 3-7 cycloalkyl.
  • R 3 is cyclopropyl, cyclobutyl, cylopentyl, or cyclohexyl.
  • R 3 is cyclopropyl.
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 monocyclic or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from N, O, and S.
  • R 3 is tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 mono or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is 4-7 membered monocyclic heterocycloalkenyl comprising one or more heteroatoms independently selected from N, O, and S.
  • R 3 is dihydropyranyl, or tetrahydropyridinyl.
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 mono or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S.
  • R 3 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl.
  • a compound of the invention is according to Formula I, wherein R 1 is C 6-10 mono or bicyclic aryl, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is phenyl substituted with one or more independently selected R 3 groups.
  • R 3 is -NHSO 2 -CH 3 , or -NHSO 2 -CH 2 CH 3 .
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl.
  • R 1 is pyrazolyl, thiazolyl, or thiophenyl.
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, optionally substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or two independently selected R 3 groups.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or two independently selected R 3 groups.
  • R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one R 3 group.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one R 3 group.
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is selected from halo, CN, and OH.
  • R 3 is selected from F, Cl, CN, and OH.
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered monocyclic or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is -CH 3 , -CH 2 CH 3 , or -CH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b .
  • each R 3 is independently selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 .
  • -CH 2 -OH, -CH 2 -OP( O) 2 OH, -C(OH)(CH 3 ) 2 , -CF 3 , -CH 2 -CHF 2 , -CH 2 CH 2 OCH 3 , and -CH 2 CH 2 N(CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is -CH 3 , -CH 2 CH 3 , or -CH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b .
  • R 3 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 3 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b , wherein R 5a is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 . In a most particular embodiment, R 3 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , or -C(CH 3 ) 3 .
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered monocyclic or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b .
  • R 3 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 3 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered monocyclic or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is C 2-4 alkenyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is C 2-4 alkenyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is C 3-7 cycloalkyl.
  • R 3 is cyclopropyl, cyclobutyl, cylopentyl, or cyclohexyl.
  • R 3 is cyclopropyl.
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered monocyclic or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from N, O, and S.
  • R 3 is tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl.
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered monocyclic or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is 4-7 membered monocyclic heterocycloalkenyl comprising one or more heteroatoms independently selected from N, O, and S.
  • R 3 is dihydropyranyl, or tetrahydropyridinyl.
  • a compound of the invention is according to Formula I, wherein R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, or S.
  • R 3 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl.
  • a compound of the invention is according to any one of Formula I, wherein R 1 is 5-10 membered mono or fused bicyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, and R 3 is as described above.
  • R 1 is furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, pyridazinyl, pyrimidyl, or pyrazinyl, each of which is substituted with one or more independently selected R 3 groups.
  • R 3 is -NHSO 2 -CH 3 , or -NHSO 2 -CH 2 CH 3 .
  • a compound of the invention is according to Formula I, wherein R 1 is 5-6 membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, wherein two adjacent R 3 groups together with the carbon they are linked to form together a 8-10 membered fused bicycle.
  • R 1 is 5-6 membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, wherein two adjacent R 3 groups together with the carbon they are linked to form together a 8-10 membered fused bicycle.
  • R 1 is 5-6 membered monocyclic heteroaryl comprising one or more heteroatoms independently selected from N, O, and S, substituted with one or more independently selected R 3 groups, wherein two adjacent R 3 groups together with the carbon they are linked to form together a 8-10 membered fused bicycle.
  • R 1 is 5-6 membered monocyclic heteroaryl comprising one or
  • a compound of the invention is according to Formula I, wherein R 1 is C 1-6 alkyl.
  • R 1 is -CH 3 , -CH 2 -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 3 ) 2 -CH 3 , or -C(CH 3 )H-C(CH 3 ) 2 H.
  • R 1 is -C(CH 3 ) 3 , or -CH 2 CH(CH 3 ) 2 .
  • R 1 is -C(CH 3 ) 3 .
  • a compound of the invention is according to Formula I, wherein R 1 is C 1-6 alkyl substituted with one or more independently selected R 4 groups. In a particular embodiment, R 1 is C 1-6 alkyl substituted with one, two or three independently selected R 4 groups. In a more particular embodiment, R 1 is C 1-6 alkyl substituted with one R 4 group.
  • a compound of the invention is according to Formula I, wherein R 1 is C 1-6 alkyl substituted with one or more independently selected R 4 groups.
  • R 1 is -CH 3 , -CH 2 -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 3 ) 2 -CH 3 , or -CH(CH 3 )-CH(CH 3 ) 2 , each of which is substituted with one or more independently selected R 4 groups.
  • R 1 is C 1-6 alkyl substituted with one or more independently selected R 4 groups selected from F, Cl, OH, and CN.
  • R 1 is -CH 3 , -CH 2 -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 3 ) 2 -CH 3 , or -CH(CH 3 ) -CH(CH 3 ) 2 , each of which is substituted with one or more independently selected R 4 groups selected from F, Cl, OH, and CN.
  • R 1 is -CF 3 , -CH 2 CF 3 , -CH(OH)CF 3 , -CH 2 -OH, -CH 2 -CH 2 -OH, -C(CH 3 ) 2 -CH 2 -OH, -CH 2 -CN, or -CH 2 -CH 2 -CN.
  • a compound of the invention is according to Formula I, wherein R 1 is C 1-6 alkyl substituted with one or more independently selected R 4 groups.
  • R 1 is -CH 3 , -CH 2 -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 3 ) 2 -CH 3 , or -CH(CH 3 )-CH(CH 3 ) 2 , each of which is substituted with one or more independently selected R 4 groups, and R 4 is C 3-7 cycloalkyl.
  • R 1 is C 1-6 alkyl substituted with one or more independently selected R 4 groups selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • R 1 is-CH 3 , -CH 2 -CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 3 ) 2 -CH 3 , or -CH(CH 3 )-CH(CH 3 ) 2 , each of which is substituted with one or more independently selected R 4 groups selected from cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • R 1 is -CH 2 -cyclopropyl, or -CH(CH 3 )-cyclopropyl.
  • a compound of the invention is according to Formula I, wherein R 1 is C 1-6 alkyl substituted with one or more independently selected R 4 groups, wherein R 4 is C 1-4 alkoxy optionally substituted with one or more independently selected R 5c .
  • R 1 is -CH 3 , -CH 2 -CH 3 ,-CH(CH 3 ) 2 , -C(CH 3 ) 3 , -C(CH 3 ) 2 -CH 3 , or -CH(CH 3 )-CH(CH 3 ) 2 , each of which is substituted with one or more independently selected R 4 groups, wherein R 4 is C 1-4 alkoxy optionally substituted with one or more independently selected R 5c .
  • R 4 -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 each of which is optionally substituted with one or more independently selected R 5c .
  • R 4 is C 1-4 alkoxy optionally substituted with one or more independently selected R 5c , wherein R 5c is selected from F, Cl, OH, -CN, -OCH 3 , -OCH 2 CH 3 ,-NH(CH 3 ) or -N(CH 3 ) 2 .
  • R 4 is -OCH 3 , -OCH 2 -CH 3 , or -OCH(CH 3 ) 2 , each of which is substituted with one or more independently selected R 5c , and each R 5c is F, Cl, OH, -CN, -OCH 3 , -OCH 2 CH 3 ,-NH(CH 3 ) or -N(CH 3 ) 2 .
  • R 4 is -OCH 3 , -OCH 2 -CH 3 , O-CF 3 , -OCH 2 -CHF 2 , -OCH 2 CH 2 OCH 3 , or -OCH 2 CH 2 N(CH 3 ) 2 .
  • a compound of the invention is according to Formula I, wherein R 1 is wherein R 4a is C 1-5 alkyl optionally substituted with one or more independently selected halo, CN, C 1-4 alkoxy, or C 3-7 monocyclic cycloalkyl.
  • R 4a is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , or -CH 2 C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected halo, CN, C 1-4 alkoxy, or C 3-7 monocyclic cycloalkyl.
  • R 4a is C 1-5 alkyl optionally substituted with one or more independently selected F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , cyclopropyl, cyclobutyl, or cyclopentyl.
  • R 4a is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , or -CH 2 C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , cyclopropyl, cyclobutyl, or cyclopentyl.
  • R 4a is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 CH(CH 3 ) 2 , or -CH 2 C(CH 3 ) 3 .
  • R 4a is -CF 3 , -CH 2 CF 3 , or -CH 2 CN.
  • a compound of the invention is according to Formula I, wherein R 1 is wherein R 4b is C 3-7 monocyclic cycloalkyl.
  • R 4b is cyclopropyl, cyclobutyl, or cyclopentyl.
  • R 4b is cyclopropyl.
  • a compound of the invention is according to Formula IIa wherein R 3 is as described above, and the subscript n is 0, 1 or 2.
  • a compound of the invention is according to Formula IIb wherein R 3 is as described above, and the subscript n is 0, 1 or 2.
  • a compound of the invention is according to Formula IIa wherein the subscript n is 0.
  • a compound of the invention is according to Formula IIb wherein the subscript n is 0.
  • a compound of the invention is according to Formula IIa wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from halo, CN, and OH. In a more particular embodiment, each R 3 is independently selected from F, Cl, CN, and OH.
  • a compound of the invention is according to Formula IIb wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from halo, CN, and OH. In a more particular embodiment, each R 3 is independently selected from F, Cl, CN, and OH.
  • a compound of the invention is according to Formula IIa wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is independently selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , and -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b .
  • each R 3 is independently selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 .
  • -CH 2 -OH, -CH 2 -OP( O) 2 OH,-C(OH)(CH 3 ) 2 , -CF 3 , -CH 2 -CHF 2 , -CH 2 CH 2 OCH 3 , and -CH 2 CH 2 N(CH 3 ) 2 .
  • a compound of the invention is according to Formula IIb wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is independently selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , and -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b .
  • each R 3 is independently selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 .
  • -CH 2 -OH, -CH 2 -OP( O) 2 OH,-C(OH)(CH 3 ) 2 , -CF 3 , -CH 2 -CHF 2 , -CH 2 CH 2 OCH 3 , and -CH 2 CH 2 N(CH 3 ) 2 .
  • a compound of the invention is according to Formula IIa wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is independently selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , and -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b .
  • each R 3 is independently selected from C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • each R3 is independently selected from -CH 3 , -CH 2 CH 3 , CH(CH 3 ) 2 , and -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • each R 3 is independently selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 .
  • a compound of the invention is according to Formula IIb wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is independently selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , and -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b .
  • each R 3 is independently selected from C 1-4 alkyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • each R3 is independently selected from -CH 3 , -CH 2 CH 3 , CH(CH 3 ) 2 , and -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • each R 3 is independently selected from -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 .
  • a compound of the invention is according to Formula IIa wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 1-4 alkoxy, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • each R 3 is independently selected from -OCH 3 , -OCH 2 CH 3 , and -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b .
  • each R 3 is independently selected from C 1-4 alkoxy, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • each R3 is independently selected from -OCH 3 , -OCH 2 CH 3 , and -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • a compound of the invention is according to Formula IIb wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 1-4 alkoxy, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • each R 3 is independently selected from -OCH 3 , -OCH 2 CH 3 , and -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b .
  • each R 3 is independently selected from C 1-4 alkoxy, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • each R3 is independently selected from -OCH 3 , -OCH 2 CH 3 , and -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • a compound of the invention is according to Formula IIa wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 2-4 alkenyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is C 2-4 alkenyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • a compound of the invention is according to Formula IIb wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 2-4 alkenyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is as defined above.
  • R 3 is C 2-4 alkenyl, optionally substituted with one or more independently selected R 5b , wherein R 5b is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • a compound of the invention is according to Formula IIa wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 3-7 cycloalkyl. In a more particular embodiment, each R 3 is independently selected from cyclopropyl, cyclobutyl, cylopentyl, and cyclohexyl. In a most particular embodiment, R 3 is cyclopropyl.
  • a compound of the invention is according to Formula IIb wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from C 3-7 cycloalkyl. In a more particular embodiment, each R 3 is independently selected from cyclopropyl, cyclobutyl, cylopentyl, and cyclohexyl. In a most particular embodiment, R 3 is cyclopropyl.
  • a compound of the invention is according to Formula IIa wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from N, O, or S. In a particular embodiment, each R 3 is independently selected from tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, and thiomorpholinyl.
  • a compound of the invention is according to Formula IIb wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from 4-7 membered monocyclic heterocycloalkyl comprising one or more heteroatoms independently selected from N, O, or S. In a particular embodiment, each R 3 is independently selected from tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, and thiomorpholinyl.
  • a compound of the invention is according to Formula IIa wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from 4-7 membered monocyclic heterocycloalkenyl comprising one or more heteroatoms independently selected from N, O, or S. In a particular embodiment, each R 3 is independently selected from dihydropyranyl, and tetrahydropyridinyl.
  • a compound of the invention is according to Formula IIb wherein the subscript n is 1 or 2, wherein each R 3 is independently selected from 4-7 membered monocyclic heterocycloalkenyl comprising one or more heteroatoms independently selected from N, O, or S. In a particular embodiment, each R 3 is independently selected from dihydropyranyl, and tetrahydropyridinyl.
  • a compound of the invention is according to Formula IIIa or IIIb: wherein R 2 is as described above.
  • a compound of the invention is according to Formula IIIa or IIIb, wherein R 2 is selected from halo, CN, oxo, and OH. In a more particular embodiment, R 2 is selected from F, Cl, CN, oxo, and OH.
  • a compound of the invention is according to Formula IIIa or IIIb, wherein R 2 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5a , wherein R 5a is as defined above.
  • R 2 is -CH 3 , -CH 2 CH 3 , CH(CH 3 ) 2 , or -C(CH 3 ) 3 .
  • R 2 is -CH 3 , -CH 2 CH 3 , CH(CH 3 ) 2 , or -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5a .
  • R 2 is C 1-4 alkyl, optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -CH 3 , -CH 2 CH 3 , CH(CH 3 ) 2 , or -C(CH 3 ) 3 , each of which is optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -CH 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -CH 2 -OH, -C(OH)(CH 3 ) 2 , -CF 3 , -CH 2 -CHF 2 , -CH 2 CH 2 OCH 3 , or -CH 2 CH 2 N(CH 3 ) 2 .
  • a compound of the invention is according to Formula IIIa or IIIb, wherein R 2 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5a , wherein R 5a is as defined above.
  • R 2 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 .
  • R 2 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5a .
  • R 2 is C 1-4 alkoxy, optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -OCH 3 , -OCH 2 CH 3 , or -OCH(CH 3 ) 2 , each of which is optionally substituted with one or more independently selected R 5a , wherein R 5a is F, Cl, OH, CN, -OCH 3 , -OCH 2 CH 3 , -NHCH 3 , -N(CH 3 ) 2 , -NH(CH 2 -CH 3 ), -N(CH 2 -CH 3 )CH 3 , or -N(CH 2 -CH 3 ) 2 .
  • R 2 is -OCH 3 , -OCH 2 -CH 3 , O-CF 3 , -OCH 2 -CHF 2 , -OCH 2 CH 2 OCH 3 , or -OCH 2 CH 2 N(CH 3 ) 2 .
  • a compound of the invention is selected from:
  • a compound of the invention is selected from
  • the compound of the invention is selected from:
  • the compound of the invention is N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide.
  • the compound of the invention is not N-(3-carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-yl)-1H-pyrazole-5-carboxamide.
  • a compound of the invention is not an isotopic variant.
  • a compound of the invention according to any one of the embodiments herein described is present as the free base.
  • a compound of the invention according to any one of the embodiments herein described is a pharmaceutically acceptable salt.
  • a compound of the invention according to any one of the embodiments herein described is a solvate of the compound.
  • a compound of the invention according to any one of the embodiments herein described is a solvate of a pharmaceutically acceptable salt of a compound.
  • a compound of the invention may be one for which one or more variables (for example, R groups) is selected from one or more embodiments according to any of the Formula(e) listed above. Therefore, the present invention is intended to include all combinations of variables from any of the disclosed embodiments within its scope.
  • the present invention provides prodrugs and derivatives of the compounds according to the formulae above.
  • Prodrugs are derivatives of the compounds of the invention, which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention, which are pharmaceutically active, in vivo.
  • Such examples include, but are not limited to, choline ester derivatives and the like, N-alkylmorpholine esters and the like.
  • Prodrugs include acid derivatives well know to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a substituted or unsubstituted amine, or acid anhydrides, or mixed anhydrides. Simple aliphatic or aromatic esters, amides and anhydrides derived from acidic groups pendant on the compounds of this invention are preferred prodrugs.
  • double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkylesters.
  • Particularly useful are the C 1 to C 8 alkyl, C 2 -C 8 alkenyl, aryl, C 7 -C 12 substituted aryl, and C 7 -C 12 arylalkyl esters of the compounds of the invention.
  • a compound of the invention When employed as a pharmaceutical, a compound of the invention is typically administered in the form of a pharmaceutical composition. Such compositions can be prepared in a manner well known in the pharmaceutical art and comprise at least one active compound of the invention according to Formula I. Generally, a compound of the invention is administered in a pharmaceutically effective amount. The amount of compound of the invention actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound of the invention administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • compositions of this invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intra-articular, intravenous, intramuscular, and intranasal.
  • routes including oral, rectal, transdermal, subcutaneous, intra-articular, intravenous, intramuscular, and intranasal.
  • a compound of the invention is preferably formulated as either injectable or oral compositions or as salves, as lotions or as patches all for transdermal administration.
  • compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient, vehicle or carrier.
  • Typical unit dosage forms include prefilled, premeasured ampules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions.
  • a compound of the invention according to Formula I is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
  • Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like.
  • Solid forms may include, for example, any of the following ingredients, or compound of the inventions of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant
  • Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art.
  • the active compound of the invention according to Formula I in such compositions is typically a minor component, often being from about 0.05 to 10% by weight with the remainder being the injectable carrier and the like.
  • Transdermal compositions are typically formulated as a topical ointment or cream containing the active ingredient(s), generally in an amount ranging from about 0.01 to about 20% by weight, preferably from about 0.1 to about 20% by weight, preferably from about 0.1 to about 10% by weight, and more preferably from about 0.5 to about 15% by weight.
  • the active ingredients When formulated as an ointment, the active ingredients will typically be combined with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with, for example an oil-in-water cream base.
  • Such transdermal formulations are well-known in the art and generally include additional ingredients to enhance the dermal penetration of stability of the active ingredients or the formulation. All such known transdermal formulations and ingredients are included within the scope of this invention.
  • a compound of the invention can also be administered by a transdermal device. Accordingly, transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type, or of a solid matrix variety.
  • a compound of the invention can also be administered in sustained release forms or from sustained release drug delivery systems.
  • sustained release materials can be found in Remington's Pharmaceutical Sciences (Remington, 1985 ).
  • a compound of the invention according to Formula I may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
  • a minor amount of magnesium stearate may be added as a lubricant.
  • the mixture may be formed into 240-270 mg tablets (80-90 mg of active compound of the invention according to Formula I per tablet) in a tablet press.
  • a compound of the invention according to Formula I may be admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio.
  • the mixture may be filled into 250 mg capsules (125 mg of active compound of the invention according to Formula I per capsule).
  • a compound of the invention according to Formula I may be admixed with sucrose (1.75 g) and xanthan gum (4 mg) and the resultant mixture may be blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg) in water.
  • Sodium benzoate (10 mg) flavor, and color may be diluted with water and added with stirring. Sufficient water may then be added with stirring. Further sufficient water may be then added to produce a total volume of 5 mL.
  • a compound of the invention according to Formula I may be admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio.
  • a minor amount of magnesium stearate may be added as a lubricant.
  • the mixture may be formed into 450-900 mg tablets (150-300 mg of active compound of the invention according to Formula I) in a tablet press.
  • a compound of the invention according to Formula I may be dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of approximately 5 mg/mL.
  • Stearyl alcohol (250 g) and a white petrolatum (250 g) may be melted at about 75°C and then a mixture of A compound of the invention according to Formula I (50 g) methylparaben (0.25 g), propylparaben (0.15 g), sodium lauryl sulfate (10 g), and propylene glycol (120 g) dissolved in water (about 370 g) may be added and the resulting mixture may be stirred until it congeals.
  • a compound of the invention according to Formula I 50 g) methylparaben (0.25 g), propylparaben (0.15 g), sodium lauryl sulfate (10 g), and propylene glycol (120 g) dissolved in water (about 370 g) may be added and the resulting mixture may be stirred until it congeals.
  • the present invention provides compounds of the invention, or pharmaceutical compositions comprising a compound of the invention, for use in medicine.
  • the present invention provides compounds of the invention or pharmaceutical compositions comprising a compound of the invention, for use in treatment of cystic fibrosis.
  • the cystic fibrosis is caused by a Class I, II, III, IV and/or VI mutation.
  • the present invention provides compounds of the invention, or pharmaceutical compositions comprising a compound of the invention for use in the manufacture of a medicament for use in the treatment of cystic fibrosis.
  • the cystic fibrosis is caused by a Class I, II, III, IV and/or VI mutation.
  • the present invention provides pharmaceutical compositions comprising a compound of the invention, and another therapeutic agent.
  • the other therapeutic agent is a cystic fibrosis treatment agent.
  • the cystic fibrosis is caused by a Class I, II, III, IV and/or VI mutation.
  • this invention provides methods of treatment of a mammal afflicted with cystic fibrosis, which methods comprise the administration of an effective amount of a compound of the invention or one or more of the pharmaceutical compositions herein described to a patient in need thereof.
  • the cystic fibrosis is caused by a Class I, II, III, IV and/or VI mutation.
  • a compound of the invention can be administered as the sole active agent or it can be administered in combination with other therapeutic agents, including other compounds that demonstrate the same or a similar therapeutic activity and that are determined to safe and efficacious for such combined administration.
  • co-administration of two (or more) agents allows for significantly lower doses of each to be used, thereby reducing the side effects seen.
  • a compound of the invention or a pharmaceutical composition comprising a compound of the invention is administered as a medicament.
  • said pharmaceutical composition additionally comprises a further active ingredient.
  • a compound of the invention is co-administered with another therapeutic agent for the treatment of cystic fibrosis
  • therapeutic agents include but are not limited to antibiotics (for example aminoglycosides, colistin, aztreonam, ciprofloxacin azithromycin), expectorants (for example hypertonic saline, acetylcysteine, dornase alfa, denufosol), CFTR correctors (for example VX-809, VX-661, VX-983), pancreatic enzyme supplements (for example pancreatin, pancrelipase).
  • antibiotics for example aminoglycosides, colistin, aztreonam, ciprofloxacin azithromycin
  • expectorants for example hypertonic saline, acetylcysteine, dornase alfa, denufosol
  • CFTR correctors for example VX-809, VX-661, VX-983
  • any means of delivering two or more therapeutic agents to the patient as part of the same treatment regime is included any means of delivering two or more therapeutic agents to the patient as part of the same treatment regime, as will be apparent to the skilled person. Whilst the two or more agents may be administered simultaneously in a single formulation this is not essential. The agents may be administered in different formulations and at different times.
  • the compounds of the invention can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • a compound of the invention may be prepared from known or commercially available starting materials and reagents by one skilled in the art of organic synthesis.
  • Racemic mixtures were separated on a Agilent HP1100 system with UV detection.
  • Enantiomeric purity was determined on a Agilent HP1100 system with UV detection.
  • the compounds of the invention and the comparative examples can be produced according to the following schemes.
  • Phorone or 2,6-dimethyl-2,5-heptadien-4-one (1 eq) is mixed with an aqueous 1 M HCl solution and the obtained emulsion is stirred at 40°C for 6 days.
  • the water phase is extracted with DCM, and the organic phase is concentrated and purified by distillation to afford the desired product.
  • a 20 L reactor is charged with aqueous 6M HCl and is warmed up to 30 °C. Molten Phorone is added while stirring vigorously at 40°C for up to 3 h until completion. The resulting solution is then cooled to 30°C and extracted with 4 x 1 L DCM. The combined organic phases are washed with saturated NaHCO 3 solution (400 mL) and are dried over Na 2 SO 4 . The resulting crude misture is then concentrated under vacuo, and finally purified by distillation.
  • But-3-yn-2-one (Int 5, 1 eq) and diazo-acetic acid ethyl ester (Int 6, 1.1 eq) are added to a solution of InCl 3 (0.2 eq) in water and stirred for 30 min at room temperature. After overnight stirring at room temperature, the mixture is diluted with water and extracted with EtOAc. The resulting organic phase is dried and evaporated to give the desired product.
  • the amino-thiophene (1 eq) is mixed with DCM and pyridine (1.5 eq). This mixture is cooled in an ice bath.
  • the acid chloride (1.15 eq) as obtained by Method B or from a commercial source is dissolved in DCM and added to this mixture. When the addition is complete, the ice bath is removed and the resulting mixture is stirred at room temperature 1-2 hours. The mixture is then evaporated, and the residue is purified by preparative chromatography to yield the desired product.
  • a reaction vessel is charged with the amino-thiophene (1 eq), carboxylic acid (2 eq), DMAP (0.5 eq), TEA (4 eq) and 2-chloro-1-methylpyridinium iodide (2 eq) in DCM. After stirring the mixture at 50°C for 2 h, the mixture is cooled, diluted with DCM and washed with aqueous NaHCO 3 . Organic phase is dried over MgSO 4 . Evaporation gives a crude residue that is purified by preparative chromatography to yield the desired product.
  • the amine (1 eq) is mixed with the ester (10 eq) and the resuling mixture is heated at high temperature (180°C or more) in a microwave oven. After 30 min, the mixture is diluted with EtOAc and washed with brine. Evaporation of the organic phase gives a residue that is used as such in the next step.
  • the amine (100 mg, 0.39 mmol) is mixed with 2-Ethyl-malonic acid dimethyl ester (0.6 mL, 3.99 mmol) and the resuling mixture is heated 180°C in the microwave oven. After 30 min, the mixture is diluted with EtOAc and washed with brine. Evaporation of the organic phase gives a residue that is used as such.
  • the ester (1 eq) is mixed with NH 4 Cl (spatula) and a solution of NH 4 OH.
  • the resulting mixture is stirred at room temperature until the reaction is finshed.
  • Mixture is diluted with water and extracted with EtOAc.
  • Organic layer is then dried and evaporated. Desired product is obtained by chromatographic purification.
  • the alcohol (1 eq) is mixed with pyridine (1.2 eq) and DCM and the resulting solution is cooled at 0°C. After the dropwise addition of AcCl (1 eq), the mixture is stirred at room temperature for 3 h, the mixture is then washed with aqueous NH 4 Cl and the aqueous phase is extracted twice with DCM. The combined organic phases are dried over MgSO 4 , filtered and evaporated to give a residue that is used as such.
  • a solution of 1-hydroxy-cyclopropanecarboxylic acid (100 mg, 0.98 mmol) and pyridine (100 ⁇ L) in 3 mL of DCM is cooled to 0°C.
  • a solution of acetyl chloride (80 ⁇ L, 1.18 mmol) in 3 mL of DCM is then added dropwise to the ice cold mixture. After the addition, the resulting mixture is stirred at room temperature for 3h. Next, the mixture is washed with saturated NH 4 Cl. The aqueous phase is extracted twice with DCM. The combined organic phases are combined, dried over MgSO 4 , filtered, and evaporated to afford the desired product that is used as such.
  • the alcohol (400 mg, 2.5 mmol) is dissolved in dry THF (4 mL). Solution is cooled till 0°C and imidazole (238 mg, 3.5 mmol) and TBSCl (457 mg, 3.0 mmol) are added. After 30 min, the mixture is stirred at room temperature overnight. The reaction mixture is then concentrated under vacuo, and the residue is redissolved in EtOAc. This organic phase is extracted with NH 4 Cl. The organic phase is then dried over Na 2 SO 4 , filtered and evaporated to give a residue that is used as such.
  • 3-Hydroxy-butyric acid 500 mg, 4.8 mmol is dissolved in a mixture of TBSCl (1.5 g, 10.1 mmol) in dry DCM (48 mL). The resulting mixture is stirred overnight at room temperature. The resulting suspension is then filtered and the obtained residues are washed with DCM, then stirred in Et 2 O and filtered. The obtained filtrate is evaporated to give the desired product that is used as such.
  • the pyrazole (1 eq) is dissolved in dry THF at 0°C. After addition of NaH (1.5 eq), the mixture is stirred at 0°C under N 2 atmosphere for 30 min. Next, SEM-Cl (1.5 eq) is slowly added and the resulting mixture is stirred at room temperature overnight. Subsequently, the mixture is quenched with water and extracted with EtOAc. The organic phase is isolated, dried over Na 2 SO 4 , filtered and evaporated to give a residue that is used as such.
  • the pyrazole (Int 4, 2 g, 9.76 mmol) is dissolved in dry THF (20 mL) at 0°C. After addition of NaH (60w%, 584 mg, 14.6 mmol), the mixture is stirred at 0°C under N 2 atmosphere for 30 min. Next, SEM-Cl (2.58 mL, 14.6 mmol) is slowly added and the resulting mixture is stirred at room temperature overnight. Subsequently, the mixture is quenched with water and extracted with EtOAc. The organic phase is isolated, dried over Na 2 SO 4 , filtered and evaporated to give a residue that is used as such.
  • the alcohol (1 eq) is dissolved in dry THF at 0°C. After the addition of NaH (1.3 eq), the mixture is stirred at 0°C under N 2 atmosphere for 30 min. Next, SEM-Cl (1.2 eq) is slowly added and the resulting mixture is stirred at room temperature overnight. If any starting material remains, additional NaH and SEM-Cl is added. Finally, the mixture is quenched with water and extracted with EtOAc. The organic phase is isolated, dried over Na 2 SO 4 , filtered and evaporated to give a residue that is used as such.
  • LiOH (3 eq) in a MeOH-water mixture can be used instead of using K 2 CO 3 in MeOH.
  • the desired acid can also be isolated by extraction with EtOAc or DCM. Drying and evaporation of the organic solvent then gives the acid that can be used as such.
  • EtOAc or DCM Drying and evaporation of the organic solvent then gives the acid that can be used as such.
  • NaOH can also be used.
  • Dioxane can be replaced with other organic solvents that are miscible with water like MeOH or EtOH.
  • the 2-fluoropyridine is dissolved in a mixture of 6 M HCl aq and dioxane. The mixture is heated for 6 h at 70°C. Evaporation gives an aqueous phase that is quenched with a saturated K 2 CO 3 solution. The obtained suspension is filtered to give a solid that is washed with water. Trituration of this solid with MeOH gives the desired product.
  • the silyl-ether (474 mg, 0.99 mmol) is dissolved dry THF (1.5 mL) and this solution is cooled at 0°C.
  • TBAF (1.09 mL of 1 M solution in THF, 1.08 mmol) is added and the mixture is stirred at room temperature overnight.
  • the solution is diluted with a saturated NH 4 Cl solution and extracted with EtOAc. The organic phase is evaporated to give a residue that is purified by preparative chromatography to yield the desired product.
  • the SEM protected pyrazole (25 mg, 0.046 mmol) is dissolved in THF (1 mL) together with TBAF (1 M solution in THF, 136 ⁇ L, 0.438 mmol). The resulting solution is heated at 70°C overnight in a sealed microwave tube under inert atmosphere. Next, the reaction mixture is evaporated and the obtained crude is diluted with EtOAc. The organic phase is extracted with brine and evaporated to give a residue that is purified by preparative chromatography to yield the desired product.
  • the SEM protected alcohol (523 mg, 1 mmol) is dissolved in dioxane (10 mL) and a 4 M HCl in dioxane solution (0.25 mL, 1 mmol) is added to this mixture. After stirring at 50°C for 1 h, the mixture is diluted with water and extracted with EtOAc. The organic phase is dried over Na2SO4, filtered and evaporated to give a crude that is purified by preparative chromatography.
  • the phosphate ester (1eq) is dissolved in a mixture of acetone and H 2 O (1:1) and stirred at 40°C overnight. The mixture is then partially evaporated and the obtained aqueous phase made basic with an aqueous NH 4 OH solution. This solution is extracted with DCM. The aqeous solution is next acidified using 12 M HCl in H 2 O. Extraction with EtOAc gives an organic phase that is dried and evaporated. Obtained crude is purified by preparative chromatography to give the desired product. Using preparative chromatography, the 2 regio-isomers can be separated.
  • the ester is added to a mixture of 2 M HCl aq :dioxane (1:1). The resulting mixture is heated at 70°C overnight.
  • the desired product can be obtained by extraction with organic solvents like EtOAc or DCM. Alternatively, the desired product can be obtained by evaporating the reaction mixture and purifying the obtained crude by chromatography.
  • the SEM protected pyrazole (1 eq) is dissolved in THF and a 4M HCl in dioxane solution (3 eq) is added to this mixture. The mixture is stirred at 50°C. When the reaction is finished, the mixture is diluted with water and extracted with EtOAc. The organic phase is dried over Na 2 SO 4 , filtered and evaporated to give a crude that is purified by chromatography to give the desired product.
  • the ester (1 eq) is weighed in a flask together with LiBH 4 (3 eq).
  • the flask is placed in an ice bath followed by the addition of dry THF.
  • the solvent is added, the mixture is stirred at room temperature.
  • another 3 eq of LiBH 4 are added and the reaction mixture is stirred at room temperature overnight.
  • the reaction is quenched with 2 M HCl.
  • the organic solvent is evaporated and obtained mixture is extracted with DCM.
  • the organic phase is concentrated under vacuo, and the residue is purified by preparative chromatography.
  • the ester (900 mg, 2.34 mmol) is weighed together with LiBH 4 (153 mg, 7.02 mmol) in a flask.
  • the flask is put in an ice bath and dry THF (20 mL) is slowly added. After stirring for 5 min, the ice bath is removed and the mixture is stirred at room temperature. After 4 h, another portion of LiBH 4 (153 mg, 7.02 mmol) is added to the mixture at room temperature. Mixture is then stirred overnight. Reaction is subsequently quenched with 2 M HCl. Evaporation of the THF gives an aqueous phase that is extracted with DCM. The organic phase is concentrated under vacuo, and the residue is purified by preparative chromatography.
  • the enantiomerically pure compounds are obtained by purification on a chiral column.
  • the alkene (1 eq) is dissolved in MeOH together with Pd/C (10 % by weight, 0.1 eq) and a balloon of H 2 is applied. The mixture is stirred at room temperature until the reaction is finished. The mixture is then filtered over celite and the resulting liquid is concentrated to give a residue that is used as such or purified by preparative chromatography.
  • nitrile (1 eq) is dissolved in DCM and the resulting solution is cooled at -78°C under N 2 atmosphere.
  • a solution of DIBAL-H in hexane (1 M, 4 eq) is added.
  • the reaction is stirred at -78°C for 15 min, after which it is let to warm to room temperature. After overnight stirring, extra DIBAL-H is added depending on the conversion of the starting nitrile.
  • the mixture is quenched with water and Rochelle's salt. Extraction with DCM gives an organic phase that is dried and filtered over silica. After evaporation, a residue is obtained that is used as such.
  • the ester (1 eq) is dissolved in dry THF at -78°C.
  • a mixture of DIBAL-H in hexanes (2.2 eq) is added dropwise to the mixture under inert atmosphere. The mixture is stirred for 10 min at -78°C after which the mixture is allowed to reach room temperature. If the reaction is incomplete, extra eq of DIBAL-H can be added.
  • the mixture is diluted with aqueous HCl (2M) and extracted with EtOAc. Combined organic fractions are dried and evaporated. Obtained crude can be used as such or purified by chromatography to give the desired product.
  • the heteroaryl bromide (1 eq) is mixed with the boronic ester (1.25 eq), Pd(dppf)Cl 2 .DCM (0.07 eq) and DIEA (2.5 eq) in a dioxane:water mixture (2:1).
  • the reaction mixture is heated at 110°C until the reaction is finished.
  • Dilution with DCM gives an organic phase that is washed with water.
  • the organic phase is dried and evaporated to give a residue that is used as such or purified by preparative chromatography.
  • the pyrazole (Int 4, 200 mg, 0.976 mmol) is mixed with the boronic ester (256 mg, 1.22 mmol), Pd(dppf)Cl 2 .DCM (56 mg, 0.068 mmol) and DIEA (425 ⁇ L, 2.43 mmol) in a dioxane:water mixture (2:1, 3 mL).
  • the reaction mixture is heated at 110°C in the microwave for 2 h. Dilution with DCM gives an organic phase that is washed with water. Next, the organic phase is dried and evaporated to give a crude that is used as such or purified by preparative chromatography.
  • the heteroaryl bromide (1 eq) is mixed with CuI (0.05 eq) and t BuOLi (3.0 eq).
  • the alcohol is used as solvent.
  • the reaction mixture is heated at 120°C in the microwave until the reaction is finished.
  • the mixture is diluted with water and extracted with EtOAc. Organic layer is dried and evaporated to give a crude that is used such or that is purified by chromatography.
  • the pyrazole (1.10 g, 3.28 mmol) is mixed with ethylene glycol (6 mL).
  • CuI 31 mg, 0.164 mmol
  • t BuOLi 789 mg, 9.85 mmol
  • Mixture is heated in the microwave at 120°C until the reaction is finished.
  • the ester is hydrolysed.
  • the mixture is diluted with a saturated solution of NaHCO 3 and extracted with EtOAc.
  • the heteroaryl bromide (1 eq) is dissolved in dry THF at -78°C.
  • a mixture of nBuLi in hexanes (1.2 eq) is added dropwise to this mixture. After stirring for 10 min, CO 2 gas is bubbled through the mixture. The mixture is allowed to reach room temperature and quenched with water. The aqueous mixture is brought to pH ⁇ 10 and extracted with EtOAc. Aqueous layer is than acidified till pH ⁇ 3 and extracted with EtOAc. The resulting organic fraction is dried and evaporated to give a crude that is used as such.
  • the pyrazole (161 mg, 0.5 mmol) is dissolved in dry THF (3 mL) at -78°C.
  • a mixture of nBuLi in hexanes (2.5 M in hexanes, 240 ⁇ L, 0.6 mmol) is added dropwise to this mixture.
  • CO 2 gas is bubbled through the mixture.
  • the mixture is allowed to reachroom temperature and quenched with water.
  • the aqueous mixture is brought to pH ⁇ 10 and extracted with EtOAc.
  • Aqueous layer is than acidified to pH ⁇ 3 and extracted with EtOAc.
  • the resulting organic fraction is dried and evaporated to give a crude that is used as such.
  • Phosphoric acid di-tert-butyl ester chloromethyl ester (1 eq) is dissolved in DMA together with the pyrazole (1 eq) and Cs 2 CO 3 (1.25 eq). The resulting mixture is stirred at room temperature overnight. Dilution with water gives an aqueous phase that is extracted with EtOAc. Obtained organic phase is dried and evaporated to give the desired product that is used as such.
  • NXS N-halo succinimide
  • Oxone (2 eq) and NaHCO 3 (4 eq) are added to a solution of the alkene (1 eq) in a acetone:water mixture (4:1). The resulting mixture is stirred at room temperature overnight. Depending on the conversion, additional oxone and NaHCO 3 can be added to the mixture after overnight stirring. The mixture is then concentrated, diluted with EtOAc and washed with a solution of Na 2 SO 3 and water. The organic phase is dried and evaporated to give a residue that is either purified by preparative chromatography or used as such.
  • Oxone (395 mg, 0.64 mmol) and NaHCO 3 (108 mg, 1.28 mmol) are added to a solution of the alkene (120 mg, 0.32 mmol) in a acetone:water mixture (4:1, 3 mL). After stirring the resulting mixture at room temperature overnight, additional oxone and NaHCO 3 are added to the mixture. The mixture is stirred for another 4 h at room temperature. The mixture is then concentrated, diluted with EtOAc and washed with a solution of Na 2 SO 3 and water. The organic phase is dried and evaporated to give a residue that is purified by preparative chromatography to yield the desired product.
  • the solid is purified by hot trituration in ethanol. Therefore, the crude solid is suspended in absolute EtOH (16 L) for 1.5 h at 78 °C. The suspension is cooled to 20 °C and subsequently stirred for another hour. The solid product was collected by filtration, washed with 500 mL and again with 200 ml absolute EtOH, then dried to yield the desired product.
  • Example 5 Illustrative examples for the Preparation of the Comparative Compounds.
  • step i described above is subjected to Method D1 to obtain the desired compound.
  • step ii described above is (1 eq) is dissolved in a mixture of TFA and DCM at 0°C. The ice bath is allowed to melt and resulting mixture is stirred overnight at room temperature. The mixture is then diluted with DCM and extracted with a saturated NaHCO 3 solution. Trituration with di-isopropylether gives the desired compound.
  • Comparative compound A can be prepared following the same method as disclosed for Comparative Compound C, starting from commercially available 2-Amino-6-methyl-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid amide. Table II.
  • NMR Data of Representative Compounds of the Invention Cpd# ( ⁇ ) NMR data 1 1 H NMR ⁇ (ppm)(DMSO-d 6 ): 12.67 (1 H, d), 8.01 (1 H, t), 7.68 (1 H, m), 7.74 (1 H, m), 7.40 (2 H, m), 7.26 (1 H, s), 2.75 (2 H, s), 1.47 (6 H, s), 1.21 (6 H, s).
  • the YFP halide influx assay measures the functionality of the cystic fibrosis Transmembrane Conductance regulator (CFTR) channels in the cystic fibrosis bronchial epithelium cell line CFBE41o-.
  • the assay is used to evaluate the capacity of compounds to increase the open probability of existing CFTR channels in the membrane. It makes use of the observation that the yellow fluorescent protein (YFP) variant YFP H148Q, I152L has its fluorescence substantially quenched by halide ions like Cl - and I - . (Galietta et al., 2001; Nagai et al., 2002)
  • CFBE41o- cells are seeded in 96 well plates (6000 CFBE cells/well).
  • the CFBE cells are transduced with adenoviral vectors that direct the expression of the CFTR ⁇ F508 mutant and of the YFP reporter.
  • Cells are incubated at 27°C, 5% CO 2 for 24 hours so as to allow for the proper folding and migration to the membrane of the CFTR channel or treated with a CFTR modulator during 24 h at 37°C.
  • the CFTR channels are activated by treatment with the cAMP inducer forskolin (10.67 ⁇ M) and test compound in 1xD-PBS (from Gibco, Cat n# 14090-041) for 10 minutes prior to addition of an I - solution (137 mM NaI, 2.7 mM KI, 1.76 mM KH 2 PO 4 , 10.1 mM Na 2 HPO 4 , 5 mM glucose).
  • I - solution 137 mM NaI, 2.7 mM KI, 1.76 mM KH 2 PO 4 , 10.1 mM Na 2 HPO 4 , 5 mM glucose.
  • the capacity of a compound to increase the channel opening is directly correlated with the decrease in fluorescence, and is expressed as (1- (fluorescence after 7 seconds (F)/fluorescence before injection (F0))) and an EC 50 can be derived from a (1-F/F0) vs compound concentration plot.
  • Table VI EC 50 measured by YFP-halide influx assay for the CFTR- ⁇ F508 of comparative compounds.
  • the YFP halide influx assay measures the functionality of the cystic fibrosis Transmembrane Conductance regulator (CFTR) channels in the cystic fibrosis bronchial epithelium cell line CFBE41o-.
  • the assay is used to evaluate the capacity of compounds to increase the open probability of existing CFTR channels in the membrane. It makes use of the observation that the yellow fluorescent protein (YFP) variant YFP H148Q, I152L has its fluorescence substantially quenched by halide ions like Cl- and I- (Galietta et al., 2001; Nagai et al., 2002).
  • CFBE41o- cells are seeded in 384 well plates (3000 CFBE cells/well).
  • the CFBE cells are transduced with adenoviral vectors that direct the expression of the CFTR ⁇ F508 mutant and of the YFP reporter.
  • Cells are incubated at 27°C, 5% CO 2 for 24 hours so as to allow for the proper folding and migration to the membrane of the CFTR channel or treated with a CFTR modulator during 24 h at 37°C.
  • the CFTR channels are activated by treatment with the cAMP inducer forskolin (10.67 ⁇ M) and test compound in 1xD-PBS in a total volume of 30 ⁇ L (from Gibco, Cat n# 14090-041) for 10 min prior to addition of 30 ⁇ l of following I- solution (375 mM NaI, 7.5 mM KI, 1.76 mM KH 2 PO 4 , 10.1 mM Na 2 HPO 4 , 13.75 mM glucose).
  • I- induced quenching of fluorescence is recorded on an immediately after injection of I- for 2 min on an FDSS/ ⁇ Cell (Hamamatsu).
  • the capacity of a compound to increase the channel opening is directly correlated with the decrease in fluorescence, and is expressed as (1- (fluorescence after 36 seconds (F)/fluorescence before injection (F0))) and an EC50 can be derived from a (1-F/F0) vs compound concentration plot.
  • the YFP halide influx assay measures the functionality of the cystic fibrosis Transmembrane Conductance regulator (CFTR) channels.
  • the assay is used to evaluate the capacity of compounds to increase the channel opening of existing mutant CFTR channels in the membrane. It makes use of the observation that the yellow fluorescent protein (YFP) variant YFP H148Q, I152L, F47L has its fluorescence substantially quenched by halide ions like Cl - and I - .(Galietta et al., 2001)
  • HEK293- cells are seeded in 96 well plates. During seeding, the cells are reverse-transfected with plasmid vectors that direct the expression of the CFTR G551D mutant and of the YFP reporter. Cells are incubated at 37°C, 5% CO 2 for 24 hours so as to allow for sufficient expression of the CFTR protein.
  • the CFTR channels are activated by treatment with the cAMP inducer forskolin (10.67 ⁇ M) and test compound in D-PBS (Gibco) for 10 minutes prior to addition of an I - solution (137 mM NaI, 2.7 mM KI, 1.76 mM KH 2 PO 4 , 10.1 mM Na 2 HPO 4 , 5 mM glucose).
  • I - solution 137 mM NaI, 2.7 mM KI, 1.76 mM KH 2 PO 4 , 10.1 mM Na 2 HPO 4 , 5 mM glucose.
  • the capacity of a compound to increase the channel opening is directly correlated with the decrease in fluorescence, and is expressed as (1- (fluorescence after 7 seconds (F)/fluorescence before injection (F0))) and an EC 50 can be derived from a (1-F/F0) vs compound concentration plot.
  • YHA assays were developed for other channel gating defective or channel conductance defective CFTR mutants to determine effect of compound on channel activity. Examples of mutants are G178R, G1349D, S549N, R117H, R334W. This assay is also used for additional class I CFTR mutants, including G542X, W1282X; class II mutants including N1303K, and for class III mutants including S1251N; or wild-type CFTR. Table IX. EC 50 measured by YFP-halide influx assay for the CFTR-G551D of comparative compounds. Cpd# EC 50 A >10000 D >10000 E 2895 Table X.
  • Illustrative EC 50 measured by YFP-halide influx assay for the CFTR-G178R of the compounds of the invention Cpd # EC 50 (nM) 2 56.9 9 699 13 98.8 14 169 15 87.5 33 88.6 34 42.2 35 44.1 38 96.8 39 1360 40 >3330 42 156 45 368 46 19 50 47.4 52 39.7 55 58.3 71 89.3 72 31.4 76 14.1 77 2210 92 82.24 94 67.61 98 41.51 101 346.6 105 54.41 106 26 110 22.49 121 465.7 136 785.9 151 221.45 154 3330 92 82.24 94 67.61 98 41.51 101 346.6 105 54.41 106 26 110 22.49 121 465.7 136 785.9 151 221.45 154 3330 92 82.24 94 67.61 98 41.51 101 346.6 105 54.41 106 26
  • Illustrative EC 50 measured by YFP-halide influx assay for the CFTR-S549N of the compounds of the invention.
  • the YFP halide influx assay measures the functionality of the cystic fibrosis Transmembrane Conductance regulator (CFTR) channels in the cystic fibrosis bronchial epithelium cell line CFBE41o-.
  • the assay is used to evaluate the capacity of compounds to increase the open probability of existing CFTR channels in the membrane. It makes use of the observation that the yellow fluorescent protein (YFP) variant YFP H148Q, I152L has its fluorescence substantially quenched by halide ions like Cl - and I - .(Galietta et al., 2001; Nagai et al., 2002)
  • CFBE41o- cells are seeded in 96 well plates (6000 CFBE cells/well).
  • the CFBE cells are transduced with adenoviral vectors that direct the expression of the CFTR ⁇ F508 mutant and of the YFP reporter.
  • Cells are incubated at 27°C, 5% CO 2 for 24 hours so as to allow for the proper folding and migration to the membrane of the CFTR channel or treated with a CFTR modulator during 24 hours at 37°C.
  • the CFTR channels are activated by treatment with the cAMP inducer forskolin (10.67 ⁇ M) and test compound in gluconate buffer (137 mM disodiumgluconate, 2.7 mM KCl, 1.76 mM KH 2 PO 4 , 10.1 mM Na 2 HPO 4 , 5 mM glucose) for 10 minutes prior to addition of an I - solution (137 mM NaI, 2.7 mM KI, 1.76 mM KH 2 PO 4 , 10.1 mM Na 2 HPO 4 , 5 mM glucose).
  • the I - -induced quenching of fluorescence is recorded immediately after injection of I - for 7 seconds.
  • the capacity of a compound to increase the channel opening is directly correlated with the decrease in fluorescence, and is expressed as (1- (fluorescence after 7 seconds (F)/fluorescence before injection (F0))) and an EC 50 can be derived from a (1-F/F0) vs compound concentration plot.
  • Electrophysiological measurements on primary human bronchial epithelial cell cultures are a useful preclinical surrogate of clinical efficacy (Rowe and Verkman, 2013), therefore compounds are evaluated in an Ussing chamber and/or TECC assay which are electrophysiological measurement assays.
  • the Ussing chambers assay measures the functionality of the cystic fibrosis Transmembrane Conductance regulator (CFTR) by measuring the short circuit current ( I SC ) generated over the basolateral and apical membrane of lung epithelial cells.
  • CTR cystic fibrosis Transmembrane Conductance regulator
  • the epithelium is short circuited by injecting a current that is adjusted by a feed-back amplifier to keep the transepithelial potential ( V t ) at 0 mV.
  • the amount of current required is adjusted by a feedback circuit and continuously measured. Intermittently the voltage is clamped to values different from 0 mV thus enabling an estimate of the transepithelial resistance ( R t ).
  • bronchial epithelial cells isolated from CF patients homozygous for the CFTR ⁇ F508 mutation (hAEC-CF, Epithelix) or heterozygous for CFTR G551D and ⁇ F508 mutations (University of Chapel Hill, North Carolina) are plated on type IV collagen-coated Snapwell supports (Corning-Costar).
  • Human airway epithelia are generated by provision of an air-liquid interface for 21 days to form well-differentiated polarized cultures that resemble in vivo pseudo-stratified ciliated epithelium (Fulcher et al., 2005).
  • the differentiated cells are treated with 3 ⁇ M VX809 (2626 South Loop West, Suite 225, Houston, TX 77054 USA, Cat n# S1565) to allow sufficient expression of properly folded CFTR protein on the membrane (48 hours basolateral treatment and 24 hours apical treatment), prior to electrophysiological recordings.
  • VX809 2626 South Loop West, Suite 225, Houston, TX 77054 USA, Cat n# S1565
  • differentiated cells are used as such for the recordings.
  • the human airway epithelia are mounted in Ussing chambers for measurement of short-circuit current ( I SC ).
  • the epithelia are bathed in a NaCl-Ringer solution (120 mM NaCl, 25 mM NaHCO 3 , 1.2 mM CaCl 2 , 1.2 mM MgCl 2 , 0.8 mM KH 2 PO 4 , 0.8 mM K 2 HPO 4 , pH 7.4, 5 mM glucose) on the basolateral side and a glutamate-ringer solution (120 mM sodium glutamate, 25 mM NaHCO 3 , 1.2 mM CaCl 2 , 1.2 mM MgCl 2 , 0.8 mM KH 2 PO 4 , 0.8 mM K 2 HPO 4 , pH 7.4, 5 mM glucose) on the apical side to generate a Cl - gradient.
  • a NaCl-Ringer solution 120 mM NaCl, 25 mM
  • Both chambers are gassed with 95% O 2 , 5% CO 2 , and maintained at 27°C.
  • Apical amiloride is used to inhibit the endogenous ENaC currents while forkolin is applied on both apical and basolateral side to stimulate CFTR. After forskolin triggering, compounds are added on both side to test their potential for increasing CFTR gating.
  • the increase in I SC is used as a measure for the increased CFTR activity
  • EC 50 values can be generated by measuring impact of different concentrations of compound on Short circuit current on primary cells, for this purpose the same snapwell is used for the addition of increasing amounts of compound and the increase in I sc signal at each step is then transformed into a dose response curve.
  • Inh-172 an inhibitor specific for CFTR, is used to test the specificity of the tested compounds.
  • the TECC Tranepithelial Clamp Circuit, EP-design assay measures the functionality of the cystic fibrosis Transmembrane Conductance regulator (CFTR) by measuring the short circuit current ( I SC ) generated over the basolateral and apical membrane of lung epithelial cells.
  • CFTR cystic fibrosis Transmembrane Conductance regulator
  • I SC short circuit current
  • R t transepithelial resistance
  • bronchial epithelial cells isolated from CF patients homozygous for the CFTR ⁇ F508 mutation are plated on type IV collagen-coated Transwell supports (Costar).
  • Human airway epithelia are generated by provision of an air-liquid interface for 21 days to form well-differentiated polarized cultures that resemble in vivo pseudo-stratified ciliated epithelium (Fulcher et al., 2005).
  • the differentiated cells are treated with 3 ⁇ M VX809 (2626 South Loop West, Suite 225, Houston, TX 77054 USA, Cat n# S1565) to allow sufficient expression of properly folded CFTR protein on the membrane (48 hours basolateral treatment and 24 hours apical treatment), prior to electrophysiological recordings.
  • Human airway epithelia are generated by provision of an air-liquid interface for 21 days to form well-differentiated polarized cultures that resemble in vivo pseudo-stratified ciliated epithelium (Fulcher et al., 2005).
  • the differentiated cells are treated with 3 ⁇ M VX809 (2626 South Loop West, Suite 225, Houston, TX 77054 USA, Cat n# S1565) to allow sufficient expression of properly folded CFTR protein on the membrane (48 hours basolateral treatment and 24 hours apical treatment), prior to electrophysiological recordings.
  • VX809 2626 South Loop West, Suite 225, Houston, TX 77054 USA, Cat n# S1565
  • differentiated cells are used as such for the recordings.
  • Information on the compounds can be retrieved on the homozygous ⁇ F508 CFTR samples looking at increased CFTR activity when compounds are added in an acute mode or in a chronic mode. On G551D/ ⁇ F508 CFTR heterozygous samples compounds are added in an acute mode to the differentiated cells.
  • the human airway epithelia are mounted in the TECC heating plate for electrophysiological measurement and kept at 37°C.
  • the epithelia are bathed in a NaCl-Ringer solution (120 mM NaCl, 25 mM NaHCO 3 ,1.2 mM CaCl 2 , 1.2 mM MgCl 2 , 0.8 mM KH 2 PO 4 , 0.8 mM K 2 HPO 4 , pH 7.4, 5 mM glucose) on both the basolateral and apical sides.
  • a NaCl-Ringer solution 120 mM NaCl, 25 mM NaHCO 3 ,1.2 mM CaCl 2 , 1.2 mM MgCl 2 , 0.8 mM KH 2 PO 4 , 0.8 mM K 2 HPO 4 , pH 7.4, 5 mM glucose
  • Apical amiloride is used to inhibit the endogenous ENaC currents while forkolin is applied on both apical and basolateral
  • the differentiated cells are treated with 3 ⁇ M VX809 (2626 South Loop West, Suite 225, Houston, TX 77054 USA, Cat n# S1565) and potentiator compounds at different concentrations (48 hours basolateral treatment and 24 hours apical treatment), prior to electrophysiological recordings.
  • VX809 2626 South Loop West, Suite 225, Houston, TX 77054 USA, Cat n# S1565
  • potentiator compounds at different concentrations (48 hours basolateral treatment and 24 hours apical treatment)
  • the human airway epithelia are mounted in the TECC heating plate for electrophysiological measurement and kept at 37°C.
  • the epithelia are bathed in a NaCl-Ringer solution (120 mM NaCl, 25 mM NaHCO 3 ,1.2 mM CaCl 2 , 1.2 mM MgCl 2 , 0.8 mM KH 2 PO 4 , 0.8 mM K 2 HPO 4 , pH 7.4, 5 mM glucose) on both the basolateral and apical sides.
  • a NaCl-Ringer solution 120 mM NaCl, 25 mM NaHCO 3 ,1.2 mM CaCl 2 , 1.2 mM MgCl 2 , 0.8 mM KH 2 PO 4 , 0.8 mM K 2 HPO 4 , pH 7.4, 5 mM glucose
  • Apical amiloride is used to inhibit the endogenous ENaC currents while forkolin is applied on both apical and basolateral side to stimulate CFTR. Measurements are done during a 20 minute timeframe with recordings every 2 minutes.
  • I SC is used as a measure for the increased CFTR activity
  • EC 50 values can be generated by measuring impact of different concentrations of compound on I SC on primary cells, for this purpose each transwell is treated with a different compound concentration.
  • Inh-172 an inhibitor specific for CFTR, is used to test the specificity of the tested compounds.
  • Similar TECC recordings are performed using primary cells for other channel gating defective or channel conductance defective CFTR mutants to determine effect of compound on channel activity. Examples of mutants include R117H, G178R. Similarly primary cells containing class I CFTR mutants, including G542X, W1282X; and additional class II mutants including N1303K can be used for electrophysiological recordings.
  • Table XIV TECC assay results for illustrative compounds of the invention at 3 ⁇ M Cpd # ⁇ Isc ( ⁇ A/cm 2 ) ⁇ Isc ( ⁇ A/cm 2 ), DMSO Current increase ( ⁇ A/cm 2 ) 2 10.9207 -0.7427 11.6634 4 4.6728 -0.5211 5.1939 10 3.9356 -0.5211 4.4567 Table XV.
  • the compounds of the invention demonstrate an activity on the CFTR protein, at 3 ⁇ M, or 50 nM, or 50/100/200 nM whereas no such activity is measured for structural analogues (comparative compounds A, B, and E), which remain at the baseline level.
  • FRT Fish Rat Thyroid
  • G551D CFTR a low CFTR-G551D expressing cell line and a high expressing CFTR-G551D cell line from Rosalind Franklin University of medecine and science , Chicago, Illinois
  • Transwell supports Costar 6.5mm Diameter, 0.4 ⁇ M pore size
  • the cells are grown for 8-10 d under liquid-liquid interface conditions prior to electrophysiological readings.
  • the FRT-G551D cells are mounted in the TECC heating plate for electrophysiological measurement and kept at 37°C.
  • the epithelia are bathed in hepes buffered culturing medium without FBS on both the basolateral and apical sides.
  • Apical amiloride is used to inhibit the endogenous ENaC currents while forkolin is applied on both apical and basolateral side to stimulate CFTR.
  • compounds are added on both sides to test their potential for increasing CFTR gating. Measurements are done during a 10 minute timeframe with recordings every 2 min. The increase in Isc is used as a measure for the increased CFTR activity, EC50 values can be generated by measuring impact of different concentrations of compound on Isc on the cells, for this purpose each transwell is treated with a different compound concentration.
  • Inh-172 an inhibitor specific for CFTR, is used to test the specificity of the tested compounds.
  • Patch clamp is a very versatile and powerful technique which can be used to study individual ion channel activity in an isolated patch of cell membrane. Patch-clamp experiments can be performed to quantify the effects of compounds on CFTR channel activity in inside-out patches excised from cells overexpressing Wild type CFTR, ⁇ F508 CFTR or G551D CFTR channels. Specifically, the open probability of ⁇ F508, wild-type or G551D CFTR can be calculated from different patches for statistical analysis. The impact of the compound on the open probability of the CFTR channel will be compared with the open probability in absence of compound as measured or as dexribed in literature. Modulators of CFTR will increase the open probability of the mutant CFTR.
  • a solution of 1 mg/mL of the test compound is prepared in a 0.2M phosphate buffer pH 7.4 or a 0.1M citrate buffer pH 3.0 at room temperature in a glass vial.
  • the samples are rotated in a Rotator drive STR 4 (Stuart Scientific, Bibby) at speed 3.0 at room temperature for 24 h.
  • the standard curve for the compound is prepared freshly in DMSO starting from a 10mM DMSO stock solution diluted factor 2 in DMSO (5000 ⁇ M) and then further diluted in DMSO up to 19.5 ⁇ M. 3 ⁇ L of the dilution series as from 5000 ⁇ M is then transferred to a 97 ⁇ L acetonitrile-buffer mixture (50/50). The final concentration range is 2.5 to 150 ⁇ M.
  • the plate is sealed with sealing mats (MA96RD-04S, www.kinesis.co.uk) and samples are measured at room temperature on LCMS (ZQ 1525 from Waters) under optimized conditions using Quanoptimize to determine the appropriate mass of the molecule.
  • the samples are analyzed on LCMS with a flow rate of 1mL/min.
  • Solvent A is 15mM ammonia and solvent B is acetonitrile.
  • the sample is run under positive ion spray on an XBridge C18 3.5 ⁇ M (2.1 x 30mm) column, from Waters.
  • the solvent gradient has a total run time of 2 min and ranges from 5% B to 95% B.
  • Peak areas are analyzed with the aid of Masslynx software package and peak areas of the samples are plotted against the standard curve to obtain the solubility of the compound.
  • Solubility values are reported in ⁇ M or ⁇ g/mL.
  • a serial dilution of the compound is prepared in DMSO.
  • the dilution series is transferred to a 96 NUNC Maxisorb plate F-bottom (Cat no. 442404) and 0.1M phosphate buffer pH7.4 or 0.1M citrate buffer pH3.0 at room temperature is added.
  • the final concentration ranges from 300 ⁇ M to 18.75 ⁇ M in 5 equal dilution steps.
  • the final DMSO concentration does not exceed 3%.
  • 200 ⁇ M Pyrene is added to the corner points of each 96 well plate and serves as a reference point for calibration of Z-axis on the microscope.
  • the assay plates are sealed and incubated for 1 h at 37°C while shaking at 230rpm.
  • the plates are then scanned under a white light microscope, yielding individual pictures of the precipitate per concentration.
  • the precipitate is analyzed and converted into a number with a software tool which can be plotted onto a graph.
  • the first concentration at which the compound appears completely dissolved is the concentration reported; however the true concentration lies somewhere between this concentration and one dilution step higher.
  • Solubility values measured according to this protocol are reported in ⁇ g/mL.
  • a 10mM stock solution of the compound in DMSO is diluted with a factor 5 in DMSO. This solution is further diluted in freshly thawed human, rat, mouse or dog plasma (BioReclamation INC) with a final concentration of 10 ⁇ M and final DMSO concentration of 0.5% (5.5 ⁇ L in 1094.5 ⁇ L plasma in a PP-Masterblock 96well (Greiner, Cat no. 780285))
  • a Pierce Red Device plate with inserts (ThermoScientific, Cat no. 89809) is prepared and filled with 750 ⁇ L PBS in the buffer chamber and 500 ⁇ L of the spiked plasma in the plasma chamber.
  • the plate is incubated for 4 h at 37°C while shaking at 230rpm. After incubation, 120 ⁇ L of both chambers is transferred to 360 ⁇ L acetonitrile in a 96-well round bottom, PP deep-well plates (Nunc, Cat no. 278743) and sealed with an aluminum foil lid.
  • the samples are mixed and placed on ice for 30 min. This plate is then centrifuged 30 min at 1200 rcf at 4°C and the supernatant is transferred to a 96 v-bottom PP plate (Greiner, 651201) for analysis on LCMS.
  • the plate is sealed with sealing mats (MA96RD-04S) of www.kinesis.co.uk and samples are measured at room temperature on LCMS (ZQ 1525 from Waters) under optimized conditions using Quanoptimize to determine the appropriate mass of the molecule.
  • sealing mats MA96RD-04S
  • LCMS ZQ 1525 from Waters
  • the samples are analyzed on LCMS with a flow rate of 1mL/min.
  • Solvent A is 15mM ammonia and solvent B is acetonitrile.
  • the sample is run under positive ion spray on an XBridge C18 3.5 ⁇ M (2.1 x 30mm) column, from Waters.
  • the solvent gradient has a total run time of 2 min and ranges from 5% B to 95% B.
  • Peak area from the compound in the buffer chamber and the plasma chamber are considered to be 100% compound.
  • the percentage bound to plasma is derived from these results and is reported as percentage bound to plasma.
  • the solubility of the compound in the final test concentration in PBS is inspected by microscope to indicate whether precipitation is observed or not.
  • Caco-2 cells are obtained from European Collection of Cell Cultures (ECACC, cat 86010202) and used after a 21 day cell culture in 24-well Transwell plates (Fisher TKT-545-020B).
  • 2x10 5 cells/well are seeded in plating medium consisting of DMEM + GlutaMAXI + 1% NEAA + 10% FBS (FetalClone II) + 1% Pen/Strep.
  • the medium is changed every 2 - 3 days.
  • Test and reference compounds (propranolol and rhodamine123 or vinblastine, all purchased from Sigma) are prepared in Hanks' Balanced Salt Solution containing 25 mM HEPES (pH7.4) and added to either the apical (125 ⁇ L) or basolateral (600 ⁇ L) chambers of the Transwell plate assembly at a concentration of 10 ⁇ M with a final DMSO concentration of 0.25%.
  • Lucifer Yellow (Sigma) is added to the donor buffer in all wells to assess integrity of the cell layers by monitoring Lucifer Yellow permeation. As Lucifer Yellow (LY) cannot freely permeate lipophilic barriers, a high degree of LY transport indicates poor integrity of the cell layer.
  • Lucifer yellow is measured with a Spectramax Gemini XS (Ex 426nm and Em 538nm) in a clean 96 well plate containing 150 ⁇ L of liquid from basolateral and apical side.
  • P app compound acceptor final ⁇ V acceptor / compound donor initial ⁇ V donor / T inc ⁇ V donor / surface area ⁇ 60 ⁇ 10 ⁇ 6 cm / s
  • Efflux ratios as an indication of active efflux from the apical cell surface, are calculated using the ratio of P app B>A/ P app A>B.
  • the following assay acceptance criteria are used:
  • MDCKII-MDR1 cells are Madin-Darby canine kidney epithelial cells, over-expressing human multi-drug resistance (MDR1) gene, coding for P-glycoprotein (P-gp). Cells are obtained from Netherlands Cancer Institute and used after a 3-4 day cell culture in 24-well Millicell cell culture insert plates (Millipore, PSRP010R5). Bi-directional MDCKII-MDR1 permeability assay is performed as described below.
  • 3x10 5 cells/mL (1.2x10 5 cells/well) are seeded in plating medium consisting of DMEM + 1% Glutamax-100 + 1% Antibiotic/Antimycotic + 10% FBS (Biowest, S1810). Cells are left in CO 2 incubator for 3-4 days. The medium is changed 24h after seeding and on the day of experiment.
  • Test and reference compounds (amprenavir and propranolol) are prepared in Dulbecco's phosphate buffer saline (D-PBS, pH7.4) and added to either the apical (400 ⁇ L) or basolateral (800 ⁇ L) chambers of the Millicell cell culture insert plates assembly at a final concentration of 10 ⁇ M (0.5 ⁇ M in case of amprenavir) with a final DMSO concentration of 1%.
  • Lucifer Yellow 100 ⁇ M Lucifer Yellow (Sigma) is added to the all donor buffer solutions, in order to assess integrity of the cell monolayers by monitoring Lucifer Yellow permeation. Lucifer yellow is a fluorescent marker for the paracellular pathway and it is used as an internal control in every monolayer to verify tight junction integrity during the assay.
  • Lucifer yellow is measured with a Fluoroscan Ascent FL Thermo Scientific (Ex 485nm and Em 530nm) in a 96 well plate containing 150 ⁇ L of liquid from all receiver wells (basolateral or apical side).
  • a 10mM stock solution of compound in DMSO is diluted to 6 ⁇ M in a 105mM phosphate buffer, pH7.4 in a 96 deep well plate (Greiner, Cat no.780285) and pre-warmed at 37°C.
  • a Glucose-6-phosphate-dehydrogenase (G6PDH, Roche, 10127671001) working stock solution of 700U/mL is diluted with a factor 1:700 in a 105mM phosphate buffer, pH7.4.
  • a co-factor mix containing 0.528M MgCl 2 .6H 2 O (Sigma, M2670), 0.528M glucose-6-phosphate (Sigma, G-7879) and 0.208M NADP+ (Sigma,N-0505) is diluted with a factor 1:8in a 105mM phosphate buffer, pH7.4.
  • a working solution is made containing 1 mg/mL liver microsomes (Provider, Xenotech) of the species of interest (human, mouse, rat, dog ...), 0.8U/mL G6PDH and co-factor mix (6.6mM MgCl 2 , 6.6mM glucose-6-phosphate, 2.6mM NADP+). This mix is pre-incubated for 15 min, but never more than 20 min, atroom temperature.
  • compound dilution and the mix containing the microsomes are added together in equal amount and incubated for 30 min at 300 rpm. For the time point of 0 min, two volumes of MeOH are added to the compound dilution before the microsome mix is added. The final concentration during incubation are: 3 ⁇ M test compound or control compound, 0.5 mg/mL microsomes, 0.4U/mL G6PDH, 3.3mM MgCl 2 , 3.3mM glucose-6-phosphate and 1.3mM NaDP+.
  • samples are mixed, centrifuged and the supernatant is harvested for analysis on LC-MS/MS.
  • the instrument responses i.e. peak heights
  • the instrument responses are referenced to the zero time-point samples (as 100%) in order to determine the percentage of compound remaining.
  • Standard compounds Propanolol and Verapamil are included in the assay design.
  • microsomal stability are expressed as a percentage of the total amount of compound remaining after 30 min.
  • Rats Male, 5-6 weeks old are obtained from Janvier (France). Rats are acclimatized for at least 5 days before treatment and are kept on a 12 h light/dark cycle. Temperature is maintained at approximately 22°C, and food and water are provided ad libitum. Two days before administration of the test compounds, rats may undergo surgery to place a catheter in the jugular vein under isoflurane anesthesia. After the surgery, rats are housed individually. Rats are deprived of food for at least 16 h before oral dosing and 6 h after. Water is provided ad libitum.
  • Test compounds are formulated in PEG200/physiological saline (25/75) for the intravenous route and in 0.5% methylcellulose and EtOH/PEG 200/ Methylcellulose 0.5% (10/25/65 v/v/v) for the oral route.
  • Test compounds are orally dosed as a single esophageal gavage at 5 mg/kg under a dosing volume of 5 mL/kg and intravenously dosed as a bolus via the caudal vein at 1 mg/kg under a dosing volume of 5 mL/kg.
  • Each group consist of 3 rats.
  • Blood samples are collected via the jugular vein with lithium heparin as anti-coagulant at the following time points: 0.05 (intravenous route), 0.25 (oral route), 0.5, 1, 3, 5, 8 and 24 h.
  • blood samples are collected at the retro-orbital sinus with lithium heparin as anti-coagulant at the following time points 0.25, 1, 3 and 6 h (oral route).
  • Whole blood samples are centrifuged at 1500 g for 10 min and the resulting plasma samples are stored at -20°C pending analysis.
  • Test compounds are formulated in 0.5% methylcellulose and EtOH/PEG 200/ Methylcellulose 0.5% (10/25/65 v/v/v) by the oral route.
  • Test compounds are orally dosed as a single esophageal gavage at 10 mg/kg under a dosing volume of 5 mL/kg.
  • Each group consists of 12 rats.
  • animals are euthanized and blood and lung samples are collected.
  • Whole blood samples are centrifuged at 1500 g for 10 min and the resulting plasma samples, along with the lung samples, are stored at -20°C pending analysis.
  • Lung samples are milled in the presence of ceramic beads and proteins present in plasma and lung samples are precipitated with an organic solvent. Concentrations of each test compound are determined by an LC-MS/MS method in which the mass spectrometer is operated in positive or negative electrospray mode.
  • Pharmacokinetic parameters are calculated using Winnonlin® or Phoenix® (Pharsight®, United States).
  • the lung-to-plasma ratio is determined as the ratio between compound concentration in lung and in plasma.
  • mean, standard error of the mean (sem) and coefficient of variation (CV%) are calculated using data from three animals.
  • the assay allows determining the CYP induction activity of a compound, using Human Pregnane X Receptor (PXR), which primary function is to up regulate the synthesis of the cytochrome P450 in the presence of toxic agents.
  • PXR Human Pregnane X Receptor
  • Transcriptional activation is monitored by luminescence. Data are expressed as fold activation relative to the vehicle control.
  • the use of 5 or more doses of test compound and positive control allows for the derivation of EC 50 and Emax values from nonlinear regression analysis of the log dose-response curves.
  • Test compound values are compared to those obtained for the positive control (10 ⁇ M rifampicin).
  • the assay measures the inhibition potency of a compound of the major CYP450 isoenzymes.
  • test compound A 5 mM stock solution of test compound is prepared in methanol. This stock is serially diluted 1:3 in methanol followed by a 50 fold dilution in 50 mM potassium phosphate buffer pH 7.4, resulting in seven concentrations of test compound (0.14-100 ⁇ M, 2% methanol).
  • the obtained compound dilution is added to human hepatic microsomes at 20mg protein/mL (BD Biosciences, either Cat.No. 452161, or alternatively Cat.No. 452117) and probe substrate (see table below).
  • reaction After pre-warming the solution for 5 min at 37°C, the reaction is started by adding cofactor mix (7.65 mg/mL glucose-6-phosphate, 1.7 mg/mL NADP, 6U/mL of glucose-6-phosphate dehydrogenase).
  • reaction 50 ⁇ L is terminated by adding 150 ⁇ L of an acetonitrile:methanol (2:1) solution with internal standard (warfarin). Samples are centrifuged (535 g, 25 min, +4°C) and the supernatant fractions analyzed by LC-MS/MS.
  • the aim of this assay is to evaluate which of the major CYP450 isoenzyme(s) may be involved in the metabolism of a test compound.
  • a 1 mM stock solution of test compound is prepared in DMSO. This stock is diluted in 50 mM potassium phosphate buffer pH 7.4, resulting in a final assay concentration of test compound of 1 ⁇ M, 01% DMSO. This compound dilution is added to cDNA-expressed human cytochrome P450 isoenzymes (BD Biosciences, Cat N° CYP1A2: 456203; CYP2C19: 456259; CYP2C9: 456258; CYP3A4: 456202; CYP2D6: 456217), specific conditions depended on the isoform studies: see Table below.
  • reaction concentrations in the assay were: 0.6 U/ml Glucose-6-phophate-dehydrogenase (G6PDH), 3.3 mM MgCl 2 , 3.3 mM glucose-6-phosphate and 1.3 mM NADP+ for CYP3A4, CYP2C9, CYP2C19 and CYP1A2. And 0.6 U/mL G6PDH, 0.41 mM MgCl 2 , 0.41 mM glucose-6-phosphate and 8.2 ⁇ M NADP+ for CYP2D6).
  • a stability control is performed by incubating the test compound with denaturated (by heat) enzymes and cofactor mix to evaluate the stability of thereof during the incubation time.
  • samples 50 ⁇ L are terminated with 100 ⁇ L acetonitrile solution with internal standard (warfarin).
  • Samples are centrifuged (805 g, 20 minutes, +4°C) and the supernatant fractions are filtered (Varian Captiva Cat N°: A5960002), diluted in water/acetonitrile (85/15) and analyzed by LC-MS/MS (see Table 3).
  • the instrument responses ratio of test compound and internal standard peak areas are referenced to the zero time-point samples (100%) in order to determine the percentage of compound remaining.
  • the mechanism-based inhibition assay for CYP3A4 is carried out to evaluate the presence of any TDI.
  • test compound A 5 mM stock solution of test compound is prepared in methanol. This stock is serially diluted 1:3 in methanol and then added in duplicates to mixture containing 50 mM potassium phosphate buffer pH 7.4 and human liver microsomes (BD Gentest). Final reaction conditions are as follows: seven test compound concentrations (0.14 - 100 ⁇ M), prepared in duplicates and 2% methanol.
  • Cytochrome P450 Isoform Microsomes (mg/ml) Probe compound Probe metabolite Incubation (min) Positive Control Negative Control 3A4 0.1 Midazolam (3 ⁇ M) 1'-OH-midazolam 5 Troleandomycin Ketoconazole 3A4 0.25 Testosterone (100 ⁇ M) 6 ⁇ -OH-testosterone 15 Troleandomycin Ketoconazole
  • the 20 min pre-incubation is started by adding a probe substrate to the first concentration range (first replica) and a co-factor mix (7.65 mg/mL glucose-6-phosphate, 1.7 mg/mL NADP, 6U/mL of glucose-6-phosphate dehydrogenase) to the second replica.
  • the reaction is finally started by adding the co-factor mix to the first replica and probe substrate to second replica (opposite from pre-incubation).
  • Percent of control activity vs concentration plots are generated and fitted using GraphPad Prism software to determine IC 50 for both substrate- and co-factor pre-incubations, as well as the IC 50 fold shift.
  • IC 50 for Compound 2 is > 100 ⁇ M, both without and with preincubation using Midazolam or testosterone as probe substrate, indicating no evidence for time-dependent inhibition of CYP3A4.
  • the compounds of the invention surprisingly exhibit significant improvement in vitro in potency in the CFTR- ⁇ F508 and CFTR-G551D mutation YFP halide influx assay over close analogues: for example Compound 3 (Compound of the invention) vs comparative Compound D, or Compound 2 (Compound of the invention) vs comparative Compound E.
  • Compound 2 surprisingly shows an activity not observed for closely related analogues comparative Compounds A, B, or E.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP18181140.7A 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators Withdrawn EP3486246A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13179671 2013-08-08
GB201317935A GB201317935D0 (en) 2013-10-10 2013-10-10 Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
PCT/EP2014/066806 WO2015018823A1 (en) 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators
EP14749783.8A EP3030568B1 (en) 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/EP2014/066806 Previously-Filed-Application WO2015018823A1 (en) 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators
EP14749783.8A Division-Into EP3030568B1 (en) 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators
EP14749783.8A Division EP3030568B1 (en) 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators

Publications (1)

Publication Number Publication Date
EP3486246A1 true EP3486246A1 (en) 2019-05-22

Family

ID=51300734

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18181140.7A Withdrawn EP3486246A1 (en) 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators
EP14749783.8A Active EP3030568B1 (en) 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP14749783.8A Active EP3030568B1 (en) 2013-08-08 2014-08-05 Thieno[2,3-c]pyrans as cftr modulators

Country Status (33)

Country Link
US (4) US9133210B2 (sl)
EP (2) EP3486246A1 (sl)
JP (1) JP6425724B2 (sl)
KR (1) KR20160040295A (sl)
CN (1) CN105658655B (sl)
AU (1) AU2014304562B8 (sl)
BR (1) BR112016001984A2 (sl)
CA (1) CA2919776A1 (sl)
CL (1) CL2016000298A1 (sl)
CR (1) CR20160119A (sl)
CY (1) CY1121027T1 (sl)
DK (1) DK3030568T3 (sl)
DO (1) DOP2016000041A (sl)
ES (1) ES2691944T3 (sl)
HK (1) HK1222861A1 (sl)
HR (1) HRP20181541T1 (sl)
HU (1) HUE040366T2 (sl)
IL (1) IL243600B (sl)
LT (1) LT3030568T (sl)
LU (1) LU92577B1 (sl)
MX (1) MX2016001602A (sl)
MY (1) MY176814A (sl)
PE (1) PE20160286A1 (sl)
PH (1) PH12016500161A1 (sl)
PL (1) PL3030568T3 (sl)
PT (1) PT3030568T (sl)
RU (1) RU2708690C2 (sl)
SG (1) SG11201600891UA (sl)
SI (1) SI3030568T1 (sl)
TR (1) TR201819434T4 (sl)
TW (1) TWI649325B (sl)
UY (1) UY35700A (sl)
WO (1) WO2015018823A1 (sl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
KR20160040295A (ko) 2013-08-08 2016-04-12 갈라파고스 엔.브이. Ｃｆｔｒ 조정자로서의 티에노[2,3-ｃ]피란
WO2015160787A1 (en) 2014-04-15 2015-10-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
PE20180457A1 (es) 2015-06-02 2018-03-05 Abbvie Sarl Piridinas sustituidas y metodo de uso
US9840513B2 (en) 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
CA3001094A1 (en) 2015-10-09 2017-04-13 Abbvie S.A.R.L. Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use
AU2016333856C1 (en) 2015-10-09 2021-12-09 AbbVie Global Enterprises Ltd. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
WO2017060880A1 (en) 2015-10-09 2017-04-13 AbbVie S.à.r.l. Potentiator-corrector combinations useful in the treatment of cystic fibrosis
CN108602816A (zh) 2015-10-09 2018-09-28 艾伯维公司 用于治疗囊性纤维化的新颖化合物
KR20180102590A (ko) 2015-12-24 2018-09-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Cftr 조절제 및 이의 사용방법
EP3414235A4 (en) * 2016-02-12 2019-01-02 Vertex Pharmaceuticals (Europe) Limited Deuterium-modified cftr modulators
EP3448842A1 (en) 2016-04-26 2019-03-06 AbbVie S.À.R.L. Modulators of cystic fibrosis transmembrane conductance regulator protein
US10138227B2 (en) 2016-06-03 2018-11-27 Abbvie S.Á.R.L. Heteroaryl substituted pyridines and methods of use
US9981910B2 (en) 2016-10-07 2018-05-29 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
US10399940B2 (en) 2016-10-07 2019-09-03 Abbvie S.Á.R.L. Substituted pyrrolidines and methods of use
WO2018073175A1 (en) 2016-10-17 2018-04-26 AbbVie S.à.r.l. Compounds and pharmaceutical compositions thereof for use in the treatment of cystic fibrosis
WO2018116185A1 (en) 2016-12-20 2018-06-28 AbbVie S.à.r.l. Deuterated cftr modulators and methods of use
KR20190098204A (ko) * 2016-12-29 2019-08-21 엔요 파마 항바이러스제로서의 티오펜 유도체
TW201831471A (zh) 2017-02-24 2018-09-01 盧森堡商艾伯維公司 囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
KR20200044873A (ko) * 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CN108191885B (zh) * 2018-01-29 2020-08-04 华东师范大学 一类哌啶并噻吩类小分子有机化合物及其应用
WO2019193062A1 (en) 2018-04-03 2019-10-10 Abbvie S.Á.R.L Substituted pyrrolidines and their use
MX2020013882A (es) * 2018-06-21 2021-05-27 UCB Biopharma SRL Derivados de tiofeno para el tratamiento de trastornos causados por ige.
CN108546266B (zh) * 2018-07-25 2020-09-22 上海毕得医药科技有限公司 一种1,4,6,7-四氢吡喃[4,3-c]吡唑-3-羧酸的合成方法
EP3747882A1 (en) 2019-06-03 2020-12-09 AbbVie Overseas S.à r.l. Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2021011327A1 (en) 2019-07-12 2021-01-21 Orphomed, Inc. Compound for treating cystic fibrosis
CN114981243A (zh) 2019-11-12 2022-08-30 健赞公司 用于治疗由cftr活性缺陷介导的疾病和病状的6元杂芳基氨基磺酰胺
WO2021113806A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113809A1 (en) 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
MX2023001993A (es) 2020-08-20 2023-02-27 Univ Leland Stanford Junior Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad.
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
US20220213041A1 (en) 2021-01-06 2022-07-07 AbbVie Global Enterprises Ltd. Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
WO2023034992A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and methods of use
WO2023034946A1 (en) 2021-09-03 2023-03-09 Genzyme Corporation Indole compounds and uses thereof in the treatement of cystic fibrosis
WO2023240267A2 (en) * 2022-06-10 2023-12-14 Sionna Therapeutics Compounds, compositions, and methods of using thereof
WO2024054845A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocycic compounds, compositions, and methods of using thereof
WO2024054840A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions, and methods of using thereof
WO2024054851A1 (en) 2022-09-07 2024-03-14 Sionna Therapeutics Macrocyclic compounds, compositions and methods of using thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154888A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
JP3409029B2 (ja) 1997-10-03 2003-05-19 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害剤としてのアリールチオフェン誘導体
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
IT1313581B1 (it) 1999-07-30 2002-09-09 Recordati Chem Pharm Derivati tienopirancarbossamidici.
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
JP2002308870A (ja) 2001-04-11 2002-10-23 Rrf Kenkyusho:Kk チオフェン骨格を有する抗菌剤
CN1668308A (zh) 2002-07-29 2005-09-14 兰贝克赛实验室有限公司 作为抗菌剂的噁唑烷酮衍生物
JP2004137185A (ja) 2002-10-17 2004-05-13 Rrf Kenkyusho:Kk チオフェン骨格を有する抗菌剤
WO2004110352A2 (en) 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
AU2004270394A1 (en) * 2003-09-10 2005-03-17 Gpc Biotech Ag Heterobicyclic compounds as pharmaceutically active agents
US20050085531A1 (en) 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
DE102004024454A1 (de) 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
US20070010537A1 (en) 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
WO2006044826A2 (en) 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Thiophens and their use as anti-tumor agents
PL1828199T3 (pl) 2004-12-17 2009-10-30 Hoffmann La Roche Pochodne tieno-pirydyny jako alosteryczne wzmacniacze gaba-b
NZ570503A (en) 2006-02-15 2010-07-30 Sanofi Aventis Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
EP2019826B1 (en) 2006-05-23 2012-08-29 Vertex Pharmaceuticals, Inc. Thiophene-carboxamides useful as inhibitors of protein kinases
TW200817385A (en) 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
AU2009218861A1 (en) 2008-02-25 2009-09-03 Merck Patent Gmbh Glucokinase activators
GB0813873D0 (en) 2008-07-30 2008-09-03 Univ Dundee Compounds
US20110319416A1 (en) 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2421528A4 (en) 2009-04-20 2012-10-17 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES
US20130085133A1 (en) 2010-02-08 2013-04-04 Sourthern Research Institute Office of Commercialization and Intellectual Prop. Anti-viral treatment and assay to screenfor anti-viral agent
AU2012329913A1 (en) 2011-10-27 2014-05-22 Astellas Pharma Inc. Aminoalkyl-substituted N-thienyl benzamide derivative
WO2013129435A1 (ja) 2012-02-28 2013-09-06 協和発酵キリン株式会社 縮環チオフェン誘導体
AU2013287590B2 (en) 2012-07-12 2017-02-09 Nissan Chemical Corporation Oxime-substituted amide compound and pest control agent
DK2900674T3 (en) 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
KR20160040295A (ko) * 2013-08-08 2016-04-12 갈라파고스 엔.브이. Ｃｆｔｒ 조정자로서의 티에노[2,3-ｃ]피란

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012154888A1 (en) * 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders

Also Published As

Publication number Publication date
IL243600A0 (en) 2016-02-29
KR20160040295A (ko) 2016-04-12
HUE040366T2 (hu) 2019-03-28
CY1121027T1 (el) 2019-12-11
EP3030568B1 (en) 2018-09-19
DOP2016000041A (es) 2016-04-04
IL243600B (en) 2019-05-30
AU2014304562A1 (en) 2016-02-04
SG11201600891UA (en) 2016-03-30
US20160022633A1 (en) 2016-01-28
US9351955B2 (en) 2016-05-31
TR201819434T4 (tr) 2019-01-21
MX2016001602A (es) 2016-12-15
US20160317493A1 (en) 2016-11-03
CR20160119A (es) 2016-07-12
TWI649325B (zh) 2019-02-01
CA2919776A1 (en) 2015-02-12
DK3030568T3 (en) 2019-01-07
JP2016527296A (ja) 2016-09-08
LU92577B1 (fr) 2015-02-24
HRP20181541T1 (hr) 2018-11-16
RU2708690C2 (ru) 2019-12-11
EP3030568A1 (en) 2016-06-15
ES2691944T3 (es) 2018-11-29
AU2014304562B2 (en) 2018-05-17
US20150045327A1 (en) 2015-02-12
HK1222861A1 (zh) 2017-07-14
US20180221334A1 (en) 2018-08-09
SI3030568T1 (sl) 2019-02-28
AU2014304562B8 (en) 2018-07-05
RU2016107721A (ru) 2017-09-13
AU2014304562A8 (en) 2018-07-05
WO2015018823A1 (en) 2015-02-12
US9133210B2 (en) 2015-09-15
MY176814A (en) 2020-08-21
CN105658655A (zh) 2016-06-08
BR112016001984A2 (pt) 2017-08-01
LT3030568T (lt) 2018-12-27
CL2016000298A1 (es) 2016-11-11
US10568867B2 (en) 2020-02-25
PH12016500161A1 (en) 2016-04-25
PE20160286A1 (es) 2016-05-22
UY35700A (es) 2015-03-27
CN105658655B (zh) 2018-11-13
RU2016107721A3 (sl) 2018-04-28
PL3030568T3 (pl) 2019-03-29
US9895347B2 (en) 2018-02-20
TW201536791A (zh) 2015-10-01
JP6425724B2 (ja) 2018-11-21
PT3030568T (pt) 2018-12-24

Similar Documents

Publication Publication Date Title
US10568867B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
US9867806B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
TWI828358B (zh) 囊性纖維化跨膜傳導調節因子之調節劑、醫藥組合物、治療方法及製造該調節劑之方法
AU2021211993B2 (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
US20220306606A1 (en) Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP6779992B2 (ja) Ｎ−スルホニル化ピラゾロ［３，４−ｂ］ピリジン−６−カルボキサミドおよび使用法
JP2022009448A (ja) ヘテロアリール置換されたピリジン類及び使用方法
TW202115092A (zh) 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN109641873B (zh) N-(吡啶-2-基)吡啶-磺酰胺衍生物及其用于疾病治疗的用途
KR20110082189A (ko) 아밀로이드 베타의 조절제
CA2709301A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator
WO2021020585A1 (ja) 複素環化合物
Class et al. Patent application title: NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF CYSTIC FIBROSIS Inventors: Steven Emiel Van Der Plas (Mechelen, BE) Hans Kelgtermans (Mechelen, BE) Sébastien Jean Jacques Cédric Dropsit Montover (Mechelen, BE) Sebastien Laurent Xavier Martina (Mechelen, BE) Martin James Inglis Andrews (Mechelen, BE)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 3030568

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191123